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ABSTRACT 
OBJECTIVES: Control of the TB epidemic is a global health priority and one that is 
only likely to be achieved through vaccination. The critical overlap with the HIV 
epidemic requires any effective TB vaccine regimen to be safe in individuals who are 
infected with HIV. The objectives of this clinical trial were to evaluate the safety and 
immunogenicity of a leading candidate TB vaccine, MVA85A, in healthy, HIV-
infected adults. 
DESIGN: This was an open-label Phase I trial, performed in 20 healthy HIV-
infected, antiretroviral-naïve subjects. Two different doses of MVA85A were each 
evaluated as a single immunisation in 10 subjects, with 24 weeks of follow-up.  Safety 
of MVA85A was assessed by clinical and laboratory markers, including regular CD4 
counts and HIV RNA load measurements. Vaccine immunogenicity was assessed by 
ex-vivo IFN-γ ELISpot assays and flow cytometric analysis. 
RESULTS: MVA85A was safe in subjects with HIV infection, with an adverse event 
profile comparable to previous trials in HIV-uninfected subjects. There were no 
clinically significant vaccine-related changes in CD4 count or HIV RNA load in any 
subjects, and no evidence from qPCR analyses to indicate that MVA85A vaccination 
leads to widespread preferential infection of vaccine-induced CD4+ T cell 
populations. Both doses of MVA85A induced an antigen-specific IFN-γ response that 
was durable for 24 weeks, although of a lesser magnitude compared to HIV-
uninfected subjects. The functional quality of the vaccine-induced T cell response in 
HIV-infected subjects was remarkably comparable, although less durable, to that 
observed in healthy HIV-uninfected controls.  
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CONCLUSION: MVA85A is safe and immunogenic in healthy adults infected with 
HIV. Further safety and efficacy evaluation of this candidate vaccine in TB and HIV 
endemic areas is therefore merited.  
 
ARTICLE SUMMARY SECTION 
Article focus 
• HIV infection increases susceptibility to TB, and globally, TB is the cause of 
death in up to half of AIDS deaths 
• There is an urgent need for a safe and effective TB vaccine in HIV-infected 
people 
Key messages 
• MVA85A, a leading candidate TB vaccine, is safe and well tolerated  in HIV-
infected people and does not induce changes in either CD4 count or HIV RNA 
load 
• MVA85A is immunogenic in HIV-inf cted people, and induces a similar 
immune profile to that seen in HIV-uninfected people, but the immunogenicity 
is less durable in HIV-infected people.  
Strengths and limitations of this study 
• This is a Phase I study with 20 subjects, and further studies are needed in TB 
endemic countries in this important target population.  
 
 
Funding: This study was supported by The Wellcome Trust (Grant number 
WT076943MA), TBVAC (an EU 6th Framework programme grant) and The NIHR 
Oxford Biomedical Research Centre.  
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INTRODUCTION 
Tuberculosis (TB) and HIV are inextricably linked. At the end of 2007, approximately 
33.2 million persons were living with Human Immune Deficiency Virus-1 (HIV) 
infection, an estimated one-third of whom were co-infected with Mycobacterium 
tuberculosis (M. tuberculosis)1. TB is the cause of death for up to half of all AIDS 
patients2  and the increasing incidence of drug-resistant strains of M. tuberculosis 
poses a significant threat to a susceptible HIV-infected population 3. 
Mycobacterium bovis (M. bovis) Bacille Calmette Guérin (BCG) fails to  protect 
consistently against the adult pulmonary form of TB, whilst providing reliable 
protection against disseminated infection in childhood 4. An improved vaccine 
strategy is thus essential for global control of this disease 5. MVA85A (modified 
vaccinia virus Ankara expressing antigen 85A) is a leading candidate TB vaccine, 
designed to enhance the effect of BCG; it is safe and highly immunogenic in healthy 
BCG-naïve and BCG-vaccinated subjects, and in subjects latently infected with M. 
tuberculosis in the UK and Africa6-11.  
It is essential that any new TB vaccine is safe in an HIV-infected population. Subunit 
vaccines are an ideal choice for an immuno-compromised population in which the 
safety of replicating whole organism vaccines may be a concern. Although MVA is a 
live viral vaccine vector, it cannot replicate in human cells 12, 13. There are now safety 
data from a number of clinical trials with recombinant MVAs in HIV-infected 
subjects, which demonstrate no sustained effect on either HIV   load or CD4 count14-
16
. Most of these studies assessed immune-reconstituted HIV-infected individuals on 
anti-retroviral therapy (ARV); however, some ARV-naïve subjects with more 
advanced HIV infection have also been vaccinated with a recombinant MVA, with no 
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significant rise in HIV load or fall in CD4 count over a 4-week follow-up period 17. 
Preclinical studies in severely immuno-suppressed macaques have also documented 
safety in this model 18. To date, MVA85A has been administered to more than 1,000 
individuals with no vaccine-related serious adverse events 6, 8-11 (McShane, 
unpublished data).  
Here we present the first clinical trial of a subunit TB vaccine in an HIV-infected 
population. This trial was designed to evaluate the safety and immunogenicity of two 
doses of MVA85A in healthy HIV-infected subjects in the UK.  
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METHODS 
Trial design and participants 
The protocol for this multi-site study was approved by the Medicines and Healthcare 
products Regulatory Agency (MHRA) and the Gene Therapy Advisory Committee 
(GTAC). Participants were recruited from the Genitourinary Medicine (GUM) 
departments at the Oxford Radcliffe Hospitals NHS Trust, University Hospitals 
Birmingham NHS Foundation Trust (Selly Oak Hospital), Great Western Hospitals 
NHS Foundation Trust, and Imperial College Healthcare NHS Trust, London.  
Potentially eligible subjects were referred to the clinical trial team. Vaccination visits 
took place in Oxford; screening and follow-up visits took place at local NHS Trust 
sites. Written informed consent was obtained from all subjects prior to enrolment in 
the trial, and the referring HIV physicians were notified.  
Eligibility required participants to be generally healthy, aged 18-55 years, with a 
normal chest radiograph and no clinical or radiological evidence of TB disease, a 
current CD4 count (measured at screening) of at least 350x106/L, a nadir CD4 count 
of not less than 300x106/L and an HIV RNA load at screening of less than 100,000 
copies/mL. All subjects were diagnosed with HIV infection at least six months before 
screening and had not received any ARVs within the preceding six months (full 
inclusion/exclusion criteria, Supplemental Methods). In all cases, testing for latent M. 
tuberculosis infection (LTBI) was conducted at screening using an in-house ex-vivo 
interferon gamma (IFN-γ) ELISpot assay for ESAT6 and CFP10 peptides. Subjects 
found to be latently infected were referred back to their consultants for possible 
treatment at the end of the trial.  
The trial was registered on a clinical trials database: ClinicalTrials.gov ID 
NCT00395720. 
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Vaccine 
Clinical grade MVA was produced under Good Manufacturing Practice standard by 
IDT Biologika GmbH. 
Procedures  
Participants were vaccinated intradermally with either 5x107 plaque-forming units 
(pfu; first group of 10 subjects) or 1x108 pfu (second group of 10 subjects). A diary 
card was completed by all subjects recording local and systemic adverse events and 
body temperature for days 1 to 7 post-vaccination. All subjects were followed up 
regularly for 12 months;   blood samples taken at each time-point for CD4 count, HIV 
RNA load measurement and cellular immunological assays. CD4 count and HIV 
RNA load results were communicated to the patient’s HIV physician at regular 
intervals. Routine haematology and biochemistry assays were performed at weeks 1 
and 12 after vaccination. All subjects attended their usual NHS follow-up 
appointments and received routine clinical care throughout the trial.  
 
Immunological assays 
Ex vivo IFN-γ ELISpot assays were performed at screening and at weeks 1, 2, 4, 12, 
and 24 post-vaccination using fresh peripheral blood mononuclear cells (PBMCs), as 
described previously 10. A single pool of 15-mer peptides spanning the Ag85A protein 
(66, overlapping by 10 amino acids, 2µg/mL final concentration of each peptide in 
each well),  and 7 pools of non-overlapping 9-10 Ag85A peptides (final concentration 
of 10µg/mL in each well) were used to stimulate for the IFN-γ ELISpot assays. For 
the 7 peptide pool wells, the results were summed across all peptide pools for each 
time-point. This potentially resulted in duplicate counting of T cells that responded to 
any of the 10mer overlap regions, since any 10mer occurred in two pools with 
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adjacent peptides, but allows direct comparison with immunogenicity data from 
previous trials.  
Intracellular cytokine staining of PBMCs was performed as described previously 19. 
Briefly, cells were stained with the amine reactive LIVE/DEAD fixable dye ViViD 
(Molecular Probes, Invitrogen) and then surface stained with monoclonal antibodies 
against CD4, CD14, CD19, CD27, CD45RO, CD57 and CCR5. After washing, cells 
were permeabilized (Cytofix/cytoperm kit; BD Pharmingen) and stained 
intracellularly for CD3, CD8, IFN-γ, TNF-α, IL-2 and MIP-1β. Naïve CD4+ memory 
cells were identified as CD45RO-CD27+CD57+; memory CD4 T cell as 
CD45RO+CD27±CD57±. CD4+ T cells producing two or more cytokines (IFN-γ, IL-
2 or TNF-α) following stimulation with Ag85A peptides were sorted to greater than 
98% purity using a modifed FACSAria flow cytometer (BD Biosciences); CMV-
specific CD4+ T cells, defined similarly, and bulk resting memory CD4+ T cells were 
sorted simultaneously Cytokine production and the expression of surface markers 
were analysed using FlowJo version 8.7 (Tree Star Inc), Pestle version 1.5 and SPICE 
version 4.1 (both from Mario Roederer, Vaccine Research Center, NIAID, NIH, 
USA). 
Real-time quantitative PCR (qPCR) was used to determine the proportion of HIV-
infected Ag85A-specific CD4+ T cells; resting memory CD4+ T cells (non-Ag85A-
specific) and CMV-specific CD4+ T cells were used as intra-individual controls. 
HIV-1 gag proviral DNA within sorted CD4+ T cell populations was quantified by 
qPCR, as described previously 20. qPCR was performed simultaneously for albumin 
gene copy number in all sorted CD4+ T cell populations to quantify cell number in 
each reaction.  
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CD4+ T cells from 12 subjects (4/10 in the low-dose group and 8/10 in the high-dose 
group) were analysed for HIV gag content; low sort yields(less than 250 antigen-
specific CD4+T cells) prevented similar analyses in the remaining 8 subjects.  
Serum levels of MIP-1α, MIP-1β, RANTES, TNF-α and IL-2 were measured pre-
vaccination and at weeks one, two and 24 post-vaccination using FlowCytomix 
simplex kits (Bender MedSystems). Serum was thawed and plated out in duplicate in  
round-bottom 96-well plates. Samples were used neat for MIP-1α, MIP-1β, TNF-α 
and IL-2, and diluted 1/10 for RANTES. Standards (provided) were reconstituted as 
specified, and 1/3 serial dilutions plated in duplicate. Bead and biotin-conjugate 
cocktails were added to each well in 25µL and 50µL volumes, respectively, and 
incubated for two hours in the dark at room temperature. Samples were then washed 
twice in 100µL Assay Buffer. Streptavidin-PE (50µL) and Assay Buffer (100µL) were 
added and plates were incubated for one hour in the dark at room temperature. 
Samples were then washed again and transferred to cluster tubes in  4% 
paraformaldehyde in PBS (400uL) and acquired using an LSRII flow cytometer (BD 
Biosciences) set up with the beads provided and the highest concentration standard;.  
the stopping gate was set so that at least 300 events were collected for each sample. 
Data were analysed using FlowCytomixPro software (Bender MedSystems). 
 
Statistical analysis 
Peak (1 week) and plateau (24 weeks) CD4+ T cell responses were compared with 
those at baseline using the Wilcoxon signed rank test, Stata Statistical Software, 
Release 9.0. 2005 (Stata Corporation, College Station, TX). Area under the curve 
(AUC) analysis was performed to compare the magnitude of vaccine-induced CD4+ T 
cell responses in each dose group. Comparisons between this trial and previous trials 
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of MVA85A, and between low and high dose groups were conducted using the Mann-
Whitney U test (Stata). 
Within-subject CD4 counts and HIV RNA load levels at weeks 1 and 24 post-
vaccination were compared with baseline levels, using a repeated measures analysis 
of variance (p-values obtained from the F-test, Stata).  
Non-parametric Spearman rank analyses were used to correlate immune assays and 
CD4/HIV RNA load with CD4+ T cell responses. 
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RESULTS 
Thirty-five individuals attended for screening between October 2006 and June 2009; 
20 subjects were enrolled (Fig. 1, consort). The demographics of the 20 participants 
are shown in Table 1, and were comparable across the two groups.  
 
Local reactions related to the MVA vaccine occur during the first week after 
vaccination and have been reported previously 6, 7, 10. The local adverse event (AE) 
profile recorded in the diary cards of the HIV-infected subjects in this study was 
comparable to that observed in HIV-uninfected subjects, although pruritis appeared 
slightly higher in the HIV-infected group (Table 2a).  
 
One subject in the low dose group experienced a single episode of fever greater than 
37.5 oC (documented at 38.1oC). All other subjective systemic symptoms occurred 
with similar frequencies in the low dose and high dose groups (Table 2b).  
 
Pre-vaccination CD4 counts and HIV RNA loads for all 20 subjects over a time 
period of one to six years before enrolment are shown in Figure 2. These longitudinal 
data illustrate the levels of natural fluctuation that occur over time and represent 
important baseline measurements for the interpretation of these parameters post-
vaccination, also shown in Figure 2, in the absence of an unvaccinated control group. 
A repeated measures analysis of variance showed no evidence of a difference in either 
CD4 counts or HIV RNA load levels pre- and post- vaccination (low dose, CD4 
count: p=0.35; low dose, HIV RNA load: p=0.30; high dose, CD4 count: p=0.83; high 
dose, HIV RNA load: p=0.48). 
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A major concern with respect to the vaccination of HIV-infected individuals is the 
possibility that responding antigen-specific CD4+ T cells will act as preferential 
targets for HIV infection as a function of their activated status, thereby enhancing the 
propagation of HIV and accelerating disease progression. In this study, however, there 
was no evidence for preferential HIV infection of Ag85A-specific CD4+ T cells. The 
median number of CD4+ T cells in Ag85A-specific qPCR reactions was 73 (95% CI: 
15-130 CD4+ T cells). Where possible, multiple time-points throughout the 
vaccination course for each subject were analyzed, to determine the proportion of 
Ag85A-specific CD4+ T cells that were infected with HIV. Of 32 Ag85A-specific 
CD4+ T cell samples in total (12 subjects), only three samples from two subjects 
showed a positive signal for HIV gag DNA by qPCR: subject 1004 (week 1 post-
vaccination) and subject 1029 (weeks 2 and 8 post-vaccination) (data not shown).  In 
all 12 subjects tested, resting HIV-specific memory cell populations showed a positive 
signal in all assays (data not shown).  For CMV-specific CD4+ T cell populations, 
HIV gag DNA was detected in subjects 1004, 1029 and 1035 at the pre-vaccination 
time-points only (data not shown). All other samples were negative. In addition, 
vaccination had no effect on levels of MIP-1α, MIP-1β, RANTES, TNF-α and IL-2 in 
unstimulated serum (data not shown).  
MVA85A induced significant antigen-specific T cell responses as measured by IFN-γ 
ELISpot assay (Fig. 3a-d, Table 3a). In the low dose group, the frequency of IFN-γ-
secreting T cells responding to the single 85A peptide pool at week one post-
vaccination, increased by a median of 393 sfc/million compared to baseline 
(p=0.009); there a significant increase remained until 24 weeks post-vaccination 
(p=0.032). In the high dose group, a median increase of 502 sfc/million was apparent 
at week 1 post-vaccination (p=0.005); again, this response was maintained until 24 
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weeks (p=0.048). In both groups, T cell responses to the summed 85A peptide pools 
followed a similar pattern with a significant increase above baseline at week 1 (738 
and 1730 sfc/million for low and high dose groups, respectively), although, the week 
24 response was only maintained significantly above baseline in the high dose group 
(low dose p=0.17; high dose p=0.007). There were no significant differences in the 
magnitude of the IFN-γ response between low and high dose groups at any time-point 
(p=0.29 and p=0.68 for summed and single peptide pools, respectively; AUC analysis, 
data not shown). However the responder rate was higher in the high dose group with 
no observed non-responders compared with 1-2 non-responders (depending on 
antigen) in the low dose group. Overall, the kinetics of the Ag85A-specific T cell 
responses were very similar to those previously reported in similar studies of HIV-
uninfected subjects 6-11. 
Ag85A-specific T cell responses in the low-dose group were significantly lower 
compared to those observed in previous studies of HIV-uninfected subjects (AUC 
analysis, p=0.02; Table 3b). This difference was not significant at week 1 p=0.12, 
which represents the peak response, but was significant at week 24 post-vaccination 
(p=0.004; Table 3b, Figure 3e-g). There were no significant differences in baseline 
responses between the HIV-infected and HIV-uninfected groups (p=0.85; Table 3b). 
Similarly, HIV-infected subjects in the high dose group exhibited significantly lower 
responses compared to HIV-uninfected subjects who received the same dose of 
MVA85A (AUC analysis, p=0.0001; week 1 and week 24 p = 0.0001; Table 3b, 
Figure 3e-g). Again, baseline responses were comparable (p=0.24) (Fig. 3).  
There was a weak positive correlation between the CD4 count at screening and the 
peak summed 85A peptide pool response (R=0.04, p=0.09), and a weak negative 
correlation between HIV RNA load at screening and the peak immune response (R= -
Page 14 of 36
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
 15 
0.04, p=0.08). There was a strong negative correlation between viral load at screening 
and the plateau immune response at week 24 (R= -0.8, p=0.002).  
Four subjects were found to have LTBI. However, there were no significant post-
vaccination changes in the magnitude of ESAT-6/CFP10 responses in these subjects 
(data not shown). 
Ag85A-specific cytokine/chemokine production by CD4+ T cells prior to MVA85A 
vaccination was undetectable and increased significantly post-vaccination (Fig. 4a). 
One week following MVA85A vaccination, more than 40% of Ag85A-specific CD4+ 
T cells produced IFN-γ, IL-2, MIP-1β and TNF-α  simultaneously (p<0.01); this 
remained significant at week 2 (p<0.05). By week 8 post-vaccination, 60% of Ag85A-
specific CD4+ T cells were still producing IFN-γ, IL-2 and TNF-α simultaneously; 
production of IL-2 and IFN-γ was maintained until 24 weeks. Production of MIP-1β 
was not detected beyond week 2 post-vaccination (Fig. 4a, 5a). In the first two weeks 
post-vaccination, Ag85A-specific CD4+ T cells exhibited similar functional profiles 
in the HIV-infected groups, both low dose and high dose, and the "control" low dose 
HIV-uninfected group; in all cases, the responses were dominated by four functionally 
distinct subsets (Fig. 4b, c). IFN-γ production measured by ICS correlated closely 
with IFN-γ secretion observed in the ELISpot assay (R= 0.75, p<0.0001, n=45; data 
not shown). 
Surface expression of the HIV M-tropic co-receptor CCR5 was monitored throughout 
the course of vaccination (Fig. 5). At week 1 post-vaccination, the MFI for CCR5 was 
highest in the activated Ag85A-specific CD4+ T cells, and lowest in the naïve CD4+ 
T cell subsets. Using the integrated MFI (iMFI) function to account for cell 
frequencies, expression of CCR5 was highest in the memory CD4+ T cell pool (Fig. 
5d). No significant increase in CCR5 expression was detected in either the memory 
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(Fig. 5e) or the total (Fig. 5f) CD4+ T cell populations as a result of MVA85A 
vaccination.  
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DISCUSSION 
This is the first Phase I trial of a subunit vectored TB vaccine in HIV-infected 
individuals. Similar studies in South Africa (Tameris et al, unpublished data) and 
Senegal (Mboup et al, unpublished data) are ongoing. The two main findings of this 
study are that MVA85A is safe in healthy subjects infected with HIV (a proportion of 
whom are co-infected with M. tuberculosis), and that MVA85A is immunogenic in 
this population, albeit at a lower level than in HIV-uninfected subjects.  
 
The local and systemic AE profiles in this trial were comparable to those observed in 
HIV-uninfected subjects previously. Importantly, there were no statistically 
significant effects of vaccination on either CD4 count or HIV RNA load.  It is 
important to understand the variability in these parameters during stable untreated 
HIV infection, to enable meaningful interpretation of fluctuations throughout the trial 
period.  A recent quantitative review of cohort studies of HIV-infected adults suggests 
that, during stable untreated infection, intra-individual HIV RNA measurements can 
fluctuate over short periods of time by as much as 0.2-0.5 log10 copies/mL, with 
measurement error and physiological fluctuation each contributing about 50% of this 
variation. CD4 counts can also vary within patients by 60-130 cells/uL within weeks, 
but there is less measurement error, and during stable infection the overall within-
subject variation is proportionally larger for HIV RNA than for CD4 count 21. In this 
study, we also observed greater intra-individual variations in HIV RNA load 
compared to CD4 counts. Only one subject in each group demonstrated a more than 
0.5 log rise in HIV RNA load at week 24 post-vaccination. The first of these (low 
dose group, 008) had displayed a relatively high baseline HIV RNA load and low 
baseline CD4 count at screening, just within the inclusion criteria. As the rise in HIV 
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RNA load was only detectable 24 weeks after vaccination, it was considered highly 
unlikely that this was due to MVA85A vaccination. This subject commenced ARVs 
before week 24; all other subjects remained ARV-free throughout the trial period. The 
second subject (high dose group, 035) developed a rise in HIV RNA load between 
week 12 and week 24, peaking at just greater than a 0.5 log increase over baseline. 
However, this subject's HIV RNA load had been stable prior to this, so it was again 
deemed unlikely that this was a vaccination-related effect. Other fluctuations in the 
HIV RNA loads were observed, but any sustained rise was well within the expected 
0.5 log variation.  
HIV preferentially infects memory CD4+ T cells 22, 23, in particular HIV-specific 
memory CD4+ T cells, 20 and other activated antigen-specific CD4+ T cells 24. Using 
a sensitive qPCR method, we detected HIV gag DNA in Ag85A-specific CD4+ T 
cells from only 2/12 subjects post-vaccination. This low positivity rate concurs with 
the stable CD4 count and HIV RNA  load parameters in most subjects throughout the 
trial. Although the qPCR assay is sensitive, the low yield of Ag85A-specific CD4+ T 
cells entering the assay is an important limitation and provides just a snapshot of the 
HIV burden within the Ag85A-specific CD4+ T cell pool. However, these data 
suggest that MVA85A vaccination of healthy HIV-infected individuals does not lead 
to widespread preferential infection and depletion of vaccine-induced CD4+ T cell 
populations in the periphery. In addition, the lack of effect of vaccination on 
chemokine and cytokine levels in unstimulated serum supports the interpretation that 
vaccination with MVA85A did not lead to widespread immune activation in this 
subject group.  
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We have shown that vaccine-induced immunogenicity, while of moderate magnitude, 
is significantly lower than in healthy HIV-uninfected subjects given the same dose of 
MVA85A. Thus, additional strategies may be required to augment immune responses 
to MVA85A vaccination in the context of HIV infection. Partial reconstitution of the 
immune system with ARVs may improve the response to vaccination. Indeed, this 
study shows that the baseline HIV RNA level is a strong negative predictor of 
summed 85A peptide pool responses at week 24 post-vaccination. In addition, a 
booster vaccination with MVA85A may be required to enhance the vaccine-induced 
immune response. 
 
The functional profile of Ag85A-specific CD4+ T cells observed in this study was 
remarkably comparable to that of healthy HIV-uninfected subjects 19 and M. 
tuberculosis-infected subjects 10, although the response in HIV-infected subjects is 
less durable. IFN-γ and TNF-α are known to be important for protective immunity to 
TB, and these cytokines dominated the MVA85A vaccine-induced CD4+ T cell 
response elicited in the current study cohort. In this study, production of MIP-1β by 
Ag85A-specific CD4+ T cells was not detectable after week 2 post-vaccination. The 
production of multiple cytokines including IL-2 and MIP-1β by HIV-specific CD8+ T 
cells is associated with long-term non-progression, albeit with uncertain causality25.  
The production of β-chemokines by CD8+ T cells was not assessed here as there were 
no detectable Ag-85A specific CD8+ T cell responses pre- or post-vaccination.  
 
 Vaccine-induced bystander activation of CD4+ T cells in HIV-infected subjects is 
likely to be undesirable because activated CD4+ T cells are at increased risk of HIV 
infection. The overall pattern of cytokine production and the frequency of CMV-
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specific CD4+ T cell producing cytokines remained both relatively stable over the 24-
week period following MVA85A vaccination, and comparable to pre-vaccination 
responses (Supplemental Figure 1).  These data suggest that MVA85A vaccination 
does not induce substantial bystander activation of antigen-specific CD4+ T cell 
populations. 
 
Demonstrating the safety and immunogenicity of a new TB vaccine in an important 
target population is a crucial step, but does not mean that the vaccine will be effective. 
However, the data presented here support further safety and immunogenicity studies 
of this candidate vaccine, together with proof-of-concept efficacy trials, in TB and 
HIV endemic areas.  
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TABLE and FIGURE LEGENDS 
 
Table 1 Subject demographics: Comparison of low and high dose vaccination groups.  
 
Tables 2a and b Local and systemic adverse events: Comparison of low and high 
dose vaccination groups with dose-matched HIV-uninfected subjects from previous 
trials of MVA85A. There were significantly fewer systemic AEs per person, (and a 
lower frequency of systemic AEs overall,) in the 10 HIV-infected subjects receiving 
high dose MVA85A compared with HIV-uninfected subjects receiving the same dose 
of vaccine (p=0.026, data not shown and Pathan et al, unpublished) 
 
Table 3a Ex-vivo IFN-γ ELISpot statistics (1): Comparison of screening, week 1 and 
week 24 responses within low and high dose groups, for both summed and single 
pooled peptides, using Wilcoxon signed rank test. Median (range), median difference 
(range, of week 1 and week 24 responses compared to screening,) and p-values are 
shown. 
 
Table 3b Ex-vivo IFN-γ ELISpot statistics (2): Comparison of responses between 
HIV-infected and HIV-uninfected subjects, at each time-point and each vaccine dose, 
using Mann-Whitney U test. Median (range), difference in medians (with 95% 
confidence intervals), and p-values are shown. AUC analysis is also shown. 
 
Figure 1 Consort flowcharts. Follow-up was conducted for 24 weeks post-
vaccination in both the low dose MVA85A (5x107pfu; left panels) and high dose 
MVA85A (1x108 pfu; right panels) groups. Of the volunteers excluded at screening, 
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5/15 had CD4 counts <350 x 106/L and/or exhibited progressively decreasing CD4 
counts, 2/15 had HIV RNA loads of >100,000 copies/mL, 2/15 had abnormal chest 
radiographs, 1/15 had a current history of active eczema, and 1/15 had a history of 
illicit drug usage and unstable depression; the remaining 4/15 were eligible but failed 
to attend for vaccination (2 in each dose group).  
 
Figure 2 (a-d) Comparison of pre and post-vaccination CD4 counts: Longitudinal 
CD4 counts of subjects in the low dose (5x107 pfu MVA85A) group pre-vaccination, 
(a); and high dose (1x108 pfu MVA85A) group (c) pre-vaccination. Longitudinal CD4 
counts post-vaccination (up to 24 weeks) in the low dose (b) and high dose (d) 
groups. NB X-axis for the pre-vaccination data is not standardised for time but varies 
from 1-6 years depending on the individual subject.(e-h) Comparison of pre and post-
vaccination HIV RNA loads: Longitudinal HIV RNA loads of subjects in the low dose 
(e) and high dose (g) groups pre-vaccination. Longitudinal HIV RNA loads post-
vaccination (up to 24 weeks) in the low dose (f) and high dose (h) groups. 
Anonymous number codes (001-036) shown in key. NB X-axis for the pre-
vaccination data is not standardised for time but varies from 1-6 years depending on 
the individual subject. 
 
Figure 3 (a-d) IFN-γ ELISpot responses in the low dose and high dose groups. 
Longitudinal responses to the single 85A peptide pool are shown for the low dose 
(5x107 pfu MVA85A) group, (a) and high dose (1x108 pfu MVA85A) group (b). 
Longitudinal responses to the summed 85A peptide pools are shown for the low dose 
(c) and high dose (d) groups. Horizontal bars represent the median response.  
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Comparison of IFN-γ ELISpot responses in HIV-infected and HIV-uninfected subjects 
(e-g). Responses to summed 85A peptide pools for low dose and high dose vaccine 
regimes at screening (e); week 1 post-vaccination (f) and week 24 post-vaccination 
(g).  Subjects with LTBI are denoted with grey symbols. Statistically significant 
differences in the responses between HIV-infected and HIV-uninfected subjects were 
assessed using the Mann-Whitney U test. *p<0.05; **p<0.01; ***p<0.001. Horizontal 
bars represent the median response.  
 
Figure 4 MVA85A induces polyfunctional Ag85A-specific CD4+ T cells in HIV-
infected individuals. MVA85A vaccination-induced production of IFN-γ, IL-2, MIP-
1β and TNF-α by antigen-specific CD4+ T cells was assessed following Ag85A 
peptide stimulation of cryopreserved PBMC using polychromatic flow cytometry. (a) 
Individual data points are shown with median line, interquartile range (open bars) and 
range (whiskers) at baseline and at each time-point post-vaccination for every 
possible combination of cytokine/chemokine production. High dose and low dose 
groups were analyzed together (n=17). (b) The functional profile of the Ag85A-
specific CD4+ T cell response is summarized in the pie charts (n=17). CD4+ T cells 
producing a given number of cytokines/chemokines are grouped and colour-coded 
together. Pie charts are shown for the high dose HIV-infected group (n=9), the low 
dose HIV-infected group (n=8) and low dose healthy controls (n=6). (c) Absolute 
percentages of the highest frequencyCD4+ T cell subsets producing specific 
combinations of chemokine/cytokines at week 1 post-vaccination across the different 
groups; * p<0.05, ** p<0.01. 
 
Figure 5 Cytokine/chemokine production and receptor expression 
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(a) Absolute percent of Ag85A-specific CD4+ T cells producing IL-2 or MIP-1β at 
week 1 post-MVA85A vaccination in HIV-infected subjects (low dose and high dose, 
n=17) versus healthy controls (n=6). Representative histogram (b) and scatter plot (c) 
showing CCR5 median fluorescence intensity (MFI) in naïve CD4+ T cells, memory 
CD4+ T cells and activated Ag85A-specific CD4+ T cells at  week 1 post- 
vaccination (n=16 in all groups). (d) Scatter plot showing CCR5 integrated MFI 
(iMFI) for naïve, memory and Ag85A-specific CD4+ T cells (n=16). Line charts 
showing CCR5 MFI in memory CD4+ T cells (e) and the total CD4+ T cell 
population (f) across the MVA85A vaccination time-course (n=16). * p<0.05, ** 
p<0.01. 
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 28 
TABLE 1 
Demographics and screening results Low dose 
5x10
7
pfu 
High dose 
1x10
8
pfu 
Sex Male 
Female 
9 (90%) 
1 (10%) 
8 (80%) 
2 (20%) 
Median age (range) 35.8 (21-52) 35.1 (27-46) 
Continent of Birth Africa 
Asia 
Europe 
North America 
South America 
 
4 (40%) 
0 
4 (40%) 
1 (10%) 
1 (10%) 
 
4 (40%) 
1 (10%) 
5(40%) 
0 
0 
 
BCG Definite 
Uncertain 
7 (70%) 
3 (30%) 
10 (100%) 
0 (0%) 
Latent infection (ESAT-6/CFP-10 +) 2 (20%) 3 (30%) 
Median CD4 count (range) 570  
(430-1200) 
625  
(410-840) 
   
   
Median HIV RNA load (range) 6069 (39-
41890) 
14805 (49-
71090) 
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TABLE 2 
(a) 
Local Adverse Events 
  
HIV-infected 
 
HIV-negative 
Dose 
Number of subjects 
5x10
7
pfu 
n=10 
1x10
8
pfu 
n=10 
5x10
7
pfu 
n=43 
1x10
8pfu 
n=12 
Redness 10 (100%) 10 (100%) 42 (98%) 12 (100%) 
Pruritis 10 (100%) 9 (90%) 22 (51%) 8 (67%) 
Pain 8 (80%) 7 (70%) 36 (84%) 12 (100%) 
Induration 10 (100%) 10 (100%) 42 (98%) 12 (100%) 
 
(b) 
Systemic Adverse Events 
  
HIV-infected 
 
HIV-negative 
Dose 
Number of subjects 
5x10
7
pfu 
n=10 
1x10
8
pfu 
n=10 
5x10
7
pfu 
n=43 
1x10
8
pfu 
n=12 
Fever 1 (10%) 0 (0%) 3 (7%) 5 (42%) 
Feverish 3 (30%) 2 (20%) 17 (40%) 9 (75%) 
Arthralgia 2 (20%) 3 (30%) 6 (14%) 7 (58%) 
Headache 6 (60%) 4 (40%) 21 (49%) 10 (83%) 
Myalgia 1 (10%) 2 (20%) 18 (42%) 9 (75%) 
Nausea 1 (10%) 0 (0%) 4 (9%) 4 (33%) 
Vasovagal syncope 0 (0%) 1 (10%) 0 (0%) 0 (0%) 
Axillary lymphadenopathy 1 (10%) 0 (0%) 2 (5%) 2 (17%) 
Change in 
haematology/biochemistry 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
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TABLE 3 
 
(a)  
Summed pooled peptides – within dose changes from screening to peak and plateau 
 
Dose  Screening 
(n=10) 
Week 1 
(n=10) 
Week 24 
(n=10) 
Median (range) 10 (3, 20) 738 (109, 4398) 20 (0, 237) n=9 
Median difference (range) (compared to screening)  730 (109, 4383) 
 
17 (-8, 218) 
n=9 
Low 
p-value*  0.007 0.17 
Median (range) 3 (0, 14) 1730 (758, 2138) 42 (33, 256) 
Median difference (range) (compared to screening)  1721 (743, 2135) 42 (27, 247) 
High 
p-value*  0.005 0.007 
*Wilcoxon signed rank test 
 
Single pooled peptides – within dose changes from screening to peak and plateau 
 
Dose  Screening 
(n=10) 
Week 1 
(n=10) 
Week 24 
(n=10) 
Median (range) 0 (0, 8) n=9 393 (67, 1275) n=9 13 (2, 103) n=9 
Median difference (range) (compared to screening)  393 (60, 1272) 
n=9 
13 (2, 97) 
n=9 
Low 
p-value*  0.009 0.032 
Median (range) 0 (0, 8) 502 (312, 677) 14 (0, 68) 
Median difference (range) (compared to screening)  502 (294, 677) 14 (0, 66) 
High 
p-value*  0.005 0.048 
*Wilcoxon signed rank test 
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(b) 
 
HIV-infected vs. HIV-negative group 
 Summed Pooled peptides Median (range) HIV+ 
 
Median (range) HIV- 
 
Difference in medians^ 
(95% confidence interval) 
p-value* 
Low dose 738 
(109, 4398) 
n=10 
2147 
(1173, 5085) 
n=21 
1101 
(-393, 2873) 
0.12 Week 1 
High dose 1730 
(758, 2138) 
n=10 
6493 
(4854, 7312) 
n=12 
4557 
(3038, 5904) 
0.0001 
Low dose 20 
(0, 237) 
n=9 
385 
(228, 1010) 
n=20 
339 
(161, 534) 
0.004 Week 24 
High dose 42 
(33, 256) 
n=10 
970 
(655, 1199) 
n=12 
820 
(569, 1050) 
0.0001 
Low dose 2162 
(519, 23348) 
n=9 
16317 
(9129, 36418) 
n=20 
11884 
(3191, 17387) 
0.02 Area under the curve 
High dose 5929 
(3167, 11607) 
n=10 
41575 
(26919, 53807) 
n=12 
31384 
(20778, 45504) 
0.0001 
*Mann Whitney U test 
^The method used to calculate the 'difference in medians' does not simply subtract one median from the other.  All possible pairwise differences between the 2 groups are calculated and the median of these 
differences is obtained. Hence the 'difference in medians' are not exactly the differences between the entries in the 'median' columns. 
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ABSTRACT 
OBJECTIVES: Control of the TB epidemic is a global health priority and one that is 
only likely to be achieved through vaccination. The critical overlap with the HIV 
epidemic requires any effective TB vaccine regimen to be safe in individuals who are 
infected with HIV. The objectives of this clinical trial were to evaluate the safety and 
immunogenicity of a leading candidate TB vaccine, MVA85A, in healthy, HIV-
infected adults. 
DESIGN: This was an open-label Phase I trial, performed in 20 healthy HIV-
infected, antiretroviral-naïve subjects. Two different doses of MVA85A were each 
evaluated as a single immunisation in 10 subjects, with 24 weeks of follow-up.  Safety 
of MVA85A was assessed by clinical and laboratory markers, including regular CD4 
counts and HIV RNA load measurements. Vaccine immunogenicity was assessed by 
ex-vivo IFN-γ ELISpot assays and flow cytometric analysis. 
RESULTS: MVA85A was safe in subjects with HIV infection, with an adverse event 
profile comparable to previous trials in HIV-uninfected subjects. There were no 
clinically significant vaccine-related changes in CD4 count or HIV RNA load in any 
subjects, and no evidence from qPCR analyses to indicate that MVA85A vaccination 
leads to widespread preferential infection of vaccin -induced CD4+ T cell 
populations. Both doses of MVA85A induced an antigen-specific IFN-γ response that 
was durable for 24 weeks, although of a lesser magnitude compared to HIV-
uninfected subjects. The functional quality of the vaccine-induced T cell response in 
HIV-infected subjects was remarkably comparable, although less durable, to that 
observed in healthy HIV-uninfected controls.  
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CONCLUSION: MVA85A is safe and immunogenic in healthy adults infected with 
HIV. Further safety and efficacy evaluation of this candidate vaccine in TB and HIV 
endemic areas is  merited.  
 
ARTICLE SUMMARY SECTION 
Article focus 
• HIV infection increases susceptibility to TB, and globally, TB is the cause of 
death in up to half of AIDS deaths 
• There is an urgent need for a safe and effective TB vaccine in HIV-infected 
people 
Key messages 
• MVA85A, a leading candidate TB vaccine, is safe and well tolerated  in HIV-
infected people and does not induce changes in either CD4 count or HIV RNA 
load 
• MVA85A is immunogenic in HIV-infected people, and induces a similar 
immune profile to that seen in HIV-uninfected people, but the immunogenicity 
is less durable in HIV-infected people.  
Strengths and limitations of this study 
• This is a Phase I study with 20 subjects, and further studies are needed in TB 
endemic countries in this important target population.  
 
 
Funding: This study was supported by The Wellcome Trust (Grant number 
WT076943MA), TBVAC (an EU 6th Framework programme grant) and The NIHR 
Oxford Biomedical Research Centre.  
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INTRODUCTION 
Tuberculosis (TB) and HIV are inextricably linked. At the end of 2007, approximately 
33.2 million persons were living with Human Immune Deficiency Virus-1 (HIV) 
infection, an estimated one-third of whom were co-infected with Mycobacterium 
tuberculosis (M. tuberculosis)1. TB is the cause of death for up to half of all AIDS 
patients2  and the increasing incidence of drug-resistant strains of M. tuberculosis 
poses a significant threat to a susceptible HIV-infected population 3. 
Mycobacterium bovis (M. bovis) Bacille Calmette Guérin (BCG) fails to  protect 
consistently against the adult pulmonary form of TB, whilst providing reliable 
protection against disseminated infection in childhood 4. An improved vaccine 
strategy is thus essential for global control of this disease 5. MVA85A (modified 
vaccinia virus Ankara expressing antigen 85A) is a leading candidate TB vaccine, 
designed to enhance the effect of BCG; it is safe and highly immunogenic in healthy 
BCG-naïve and BCG-vaccinated subjects, and in subjects latently infected with M. 
tuberculosis in the UK and Africa6-11.  
It is essential that any new TB vaccine is safe in an HIV-infected population. Subunit 
vaccines are an ideal choice for an immuno-compromised population in which the 
safety of replicating whole organism vaccines may be a concern. Although MVA is a 
live viral vaccine vector, it cannot replicate in human cells 12, 13. There are now safety 
data from a number of clinical trials with recombinant MVAs in HIV-infected 
subjects, which demonstrate no sustained effect on either HIV   load or CD4 count14-
16
. Most of these studies assessed immune-reconstituted HIV-infected individuals on 
anti-retroviral therapy (ARV); however, some ARV-naïve subjects with more 
advanced HIV infection have also been vaccinated with a recombinant MVA, with no 
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significant rise in HIV load or fall in CD4 count over a 4-week follow-up period 17. 
Preclinical studies in severely immuno-suppressed macaques have also documented 
safety in this model 18. To date, MVA85A has been administered to more than 1,000 
individuals with no vaccine-related serious adverse events 6, 8-11 (McShane, 
unpublished data).  
Here we present the first clinical trial of a subunit TB vaccine in an HIV-infected 
population. The primary endpoint was to evaluate the safety of two doses of 
MVA85A in healthy HIV-infected subjects in the UK and the secondary endpoint was 
to evaluate the immun genicity of this vaccine regimen. .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
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Trial design and participants 
The protocol for this multi-site study was approved by the Medicines and Healthcare 
products Regulatory Agency (MHRA) and ethical approval was obtained from the 
Gene Therapy Advisory Committee (GTAC). Participants were recruited from the 
Genitourinary Medicine (GUM) departments at the Oxford Radcliffe Hospitals NHS 
Trust, University Hospitals Birmingham NHS Foundation Trust (Selly Oak Hospital), 
Great Western Hospitals NHS Foundation Trust, and Imperial College Healthcare 
NHS Trust, London.  
Potentially eligible subjects were referred to the clinical trial team. Vaccination visits 
took place in Oxford; screening and follow-up visits took place at local NHS Trust 
sites. Written informed consent was obtained from all subjects prior to enrolment in 
the trial, and the referring HIV physicians were notified.  
Eligibility required participants to be generally healthy, aged 18-55 years, with a 
normal chest radiograph and no clinical or radiological evidence of TB disease, a 
current CD4 count (measured at screening) of at least 350x106/L, a nadir CD4 count 
of not less than 300x106/L and an HIV RNA load at screening of less than 100,000 
copies/mL. All subjects were diagnosed with HIV infection at least six months before 
screening and had not received any ARVs within the preceding six months (full 
inclusion/exclusion criteria, Supplemental Methods). In all cases, testing for latent M. 
tuberculosis infection (LTBI) was conducted at screening using an in-house ex-vivo 
interferon gamma (IFN-γ) ELISpot assay for ESAT6 and CFP10 peptides. Subjects 
found to be latently infected were referred back to their consultants for possible 
treatment at the end of the trial.  
The trial was registered on a clinical trials database: ClinicalTrials.gov ID 
NCT00395720. 
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Vaccine 
Clinical grade MVA was produced under Good Manufacturing Practice standard by 
IDT Biologika GmbH. 
Procedures  
Participants were vaccinated intradermally with either 5x107 plaque-forming units 
(pfu; first group of 10 subjects) or 1x108 pfu (second group of 10 subjects). Subjects 
were sequentially allocated first to the low dose group and then once safety had been 
demonstrated, to the high dose group. A diary card was completed by all subjects 
recording local and systemic adverse events and body temperature for days 1 to 7 
post-vaccination. All subjects were followed up regularly for 12 months;   blood 
samples taken at each time-point for CD4 count, HIV RNA load measurement and 
cellular immunological assays. CD4 count and HIV RNA load results were 
communicated to the patient’s HIV physician at regular intervals. Routine 
haematology and biochemistry assays were performed at weeks 1 and 12 after 
vaccination. All subjects attended their usual NHS follow-up appointments and 
received routine clinical care throughout the trial.  
 
Immunological assays 
Ex vivo IFN-γ ELISpot assays were performed at screening and at weeks 1, 2, 4, 12, 
and 24 post-vaccination using fresh peripheral blood mononuclear cells (PBMCs), as 
described previously 10. A single pool of 15-mer peptides spanning the Ag85A protein 
(66, overlapping by 10 amino acids, 2µg/mL final concentration of each peptide in 
each well),  and 7 pools of non-overlapping 9-10 Ag85A peptides (final concentration 
of 10µg/mL in each well) were used to stimulate for the IFN-γ ELISpot assays. For 
the 7 peptide pool wells, the results were summed across all peptide pools for each 
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time-point. This potentially resulted in duplicate counting of T cells that responded to 
any of the 10mer overlap regions, since any 10mer occurred in two pools with 
adjacent peptides, but allows direct comparison with immunogenicity data from 
previous trials.  
Intracellular cytokine staining of PBMCs was performed as described previously 19. 
Briefly, cells were stained with the amine reactive LIVE/DEAD fixable dye ViViD 
(Molecular Probes, Invitrogen) and then surface stained with monoclonal antibodies 
against CD4, CD14, CD19, CD27, CD45RO, CD57 and CCR5. After washing, cells 
were permeabilized (Cytofix/cytoperm kit; BD Pharmingen) and stained 
intracellularly for CD3, CD8, IFN-γ, TNF-α, IL-2 and MIP-1β. Naïve CD4+ memory 
cells were identified as CD45RO-CD27+CD57+; memory CD4 T cell as 
CD45RO+CD27±CD57±. CD4+ T cells producing two or more cytokines (IFN-γ, IL-
2 or TNF-α) following stimulation with Ag85A peptides were sorted to greater than 
98% purity using a modifed FACSAria flow cytometer (BD Biosciences); CMV-
specific CD4+ T cells, defined similarly, and bulk resting memory CD4+ T cells were 
sorted simultaneously Cytokine production and the expression of surface markers 
were analysed using FlowJo version 8.7 (Tree Star Inc), Pestle version 1.5 and SPICE 
version 4.1 (both from Mario Roederer, Vaccine Research Center, NIAID, NIH, 
USA). 
Real-time quantitative PCR (qPCR) was used to determine the proportion of HIV-
infected Ag85A-specific CD4+ T cells; resting memory CD4+ T cells (non-Ag85A-
specific) and CMV-specific CD4+ T cells were used as intra-individual controls. 
HIV-1 gag proviral DNA within sorted CD4+ T cell populations was quantified by 
qPCR, as described previously 20. qPCR was performed simultaneously for albumin 
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gene copy number in all sorted CD4+ T cell populations to quantify cell number in 
each reaction.  
CD4+ T cells from 12 subjects (4/10 in the low-dose group and 8/10 in the high-dose 
group) were analysed for HIV gag content; low sort yields(less than 250 antigen-
specific CD4+T cells) prevented similar analyses in the remaining 8 subjects.  
Serum levels of MIP-1α, MIP-1β, RANTES, TNF-α and IL-2 were measured pre-
vaccination and at weeks one, two and 24 post-vaccination using FlowCytomix 
simplex kits (Bender MedSystems). Serum was thawed and plated out in duplicate in  
round-bottom 96-well plates. Samples were used neat for MIP-1α, MIP-1β, TNF-α 
and IL-2, and diluted 1/10 for RANTES. Standards (provided) were reconstituted as 
specified, and 1/3 serial dilutions plated in duplicate. Bead and biotin-conjugate 
cocktails were added to each well in 25µL and 50µL volumes, respectively, and 
incubated for two hours in the dark at room temperature. Samples were then washed 
twice in 100µL Assay Buffer. Streptavidin-PE (50µL) and Assay Buffer (100µL) were 
added and plates were incubated for one hour in the dark at room temperature. 
Samples were then washed again and transferred to cluster tubes in  4% 
paraformaldehyde in PBS (400uL) and acquired using an LSRII flow cytometer (BD 
Biosciences) set up with the beads provided and the highest concentration standard;.  
the stopping gate was set so that at least 300 events were collected for each sample. 
Data were analysed using FlowCytomixPro software (Bender MedSystems). 
 
Statistical analysis 
Continuous outcomes were presented as a median (range) for each group.  Median 
difference was calculated to assess difference between two groups and the 
corresponding 95% confidence interval was computed using the robust method 
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proposed by Newson21. The overall magnitude of vaccine-induced CD4+ T cell 
responses over the 24 weeks was summarised using area under the curve (AUC) for 
each dose group. Peak (1 week) and plateau (24 weeks) CD4+ T cell responses were 
compared with those at baseline (pre-vaccination) using the Wilcoxon signed rank 
test, Stata Statistical Software, Release 9.0. 2005 (Stata Corporation, College Station, 
TX). Mann-Whitney U test was used to compare between the vaccine groups. 
Comparisons between specific time points in this trial and previously published trials 
of MVA85A6, 22, and between low and high dose groups were conducted using the 
Mann-Whitney U test (Stata). 
Non-parametric Spearman rank analyses were used to correlate immune assays and 
CD4/HIV RNA load with CD4+ T cell responses. 
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RESULTS 
Thirty-five individuals attended for screening between October 2006 and June 2009; 
20 subjects were enrolled (Fig. 1, CONSORT). The demographics of the 20 
participants are shown in Table 1, and were comparable across the two groups.  
 
Safety of MVA85A in HIV-infected subjects 
Local reactions related to the MVA vaccine occur during the first week after 
vaccination and have been reported previously 6, 7, 10. The local adverse event (AE) 
profile recorded in the diary cards of the HIV-infected subjects in this study was 
comparable to that observed in HIV-uninfected subjects, although pruritis appeared 
slightly higher in the HIV-infected group (Table 2a). There were no severe local 
reactions and most local AEs were mild.  
 
One subject in the low dose group experienced a single episode of fever greater than 
37.5 oC (documented at 38.1oC). All other subjective systemic symptoms occurred 
with similar frequencies in the low dose and high dose groups (Table 2b). There was 
one moderate systemic AE and all others were mild.   
 
Pre-vaccination CD4 counts and HIV RNA loads for all 20 subjects over a time 
period of one to six years before enrolment are shown in Figure 2. These longitudinal 
data illustrate the levels of natural fluctuation that occur over time and represent 
important baseline measurements for the interpretation of these parameters post-
vaccination, also shown in Figure 2, in the absence of an unvaccinated control group. 
No clinically significant changes in CD4 counts or HIV RNA load was seen post-
vaccination.  
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A major concern with respect to the vaccination of HIV-infected individuals is the 
possibility that responding antigen-specific CD4+ T cells will act as preferential 
targets for HIV infection as a function of their activated status, thereby enhancing the 
propagation of HIV and accelerating disease progression. In this study, however, there 
was no evidence for preferential HIV infection of Ag85A-specific CD4+ T cells. The 
median number of CD4+ T cells in Ag85A-specific qPCR reactions was 73 (95% CI: 
15-130 CD4+ T cells). Where possible, multiple time-points throughout the 
vaccination course for each subject were analyzed, to determine the proportion of 
Ag85A-specific CD4+ T cells that were infected with HIV. Of 29 Ag85A-specific 
CD4+ T cell samples in total (11 subjects), only one subject showed a positive signal 
for HIV gag DNA by qPCR at two different post-vaccination timepoints (weeks 2 and 
8 post-vaccination; data not shown). In the 11 subjects tested, resting HIV-specific 
and CMV-specific memory cell populations showed a positive signal in all assays 
(data not shown). In addition, vaccination had no effect on levels of MIP-1α, MIP-1β, 
RANTES, TNF-α and IL-2 in unstimulated serum (data not shown).  
Immunogenicity of MVA85A in HIV-infected subjects 
MVA85A induced significant antigen-specific T cell responses as measured by IFN-γ 
ELISpot assay (Fig. 3a-d, Table 3a). In the low dose group, the frequency of IFN-γ-
secreting T cells responding to the single 85A peptide pool at week one post-
vaccination, increased by a median of 393 sfc/million compared to baseline 
(p=0.009); there a significant increase remained until 24 weeks post-vaccination 
(p=0.032). In the high dose group, a median increase of 502 sfc/million was apparent 
at week 1 post-vaccination (p=0.005); again, this response was maintained until 24 
weeks (p=0.048). In both groups, T cell responses to the summed 85A peptide pools 
followed a similar pattern with a significant increase above baseline at week 1 (738 
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and 1730 sfc/million for low and high dose groups, respectively), although, the week 
24 response was only maintained significantly above baseline in the high dose group 
(low dose p=0.17; high dose p=0.007). There were no significant differences in the 
overall magnitude (i.e. AUC) of the IFN-γ response between low and high dose 
groups across the follow-up period (p=0.29 and p=0.68 for summed and single 
peptide pools, respectively; data not shown). However the responder rate was higher 
in the high dose group with no observed non-responders (ie those subjects with no 
measurable vaccine induced immune response) compared with 1-2 non-responders 
(depending on antigen) in the low dose group. Overall, the kinetics of the Ag85A-
specific T cell responses were very similar to those previously reported in similar 
studies of HIV-uninfected subjects 6-11. 
Ag85A-specific T cell responses in the low-dose group were significantly lower 
compared to those observed in previously published studies of HIV-uninfected 
subjects (AUC analysis, p=0.02; Table 3b)6, 22. This difference was not significant at 
week 1 (MWU analysis, p=0.12), which represents the peak response, but was 
significant at week 24 post-vaccination (MWU analysis, p=0.004; Table 3b, Figure 
3e-g). There were no significant differences in baseline (pre-vaccination) responses 
between the HIV-infected and HIV-uninfected groups (MWU analysis, p=0.85; 
Figure 3e). Similarly, HIV-infected subjects in the high dose group exhibited 
significantly lower responses compared to HIV-uninfected subjects who received the 
same dose of MVA85A (AUC analysis, p=0.0001; week 1 and week 24 MWU 
analysis, p = 0.0001; Table 3b, Figure 3e-g). Again, baseline responses were 
comparable (p=0.24) (Fig. 3e).  
There was no significant correlation between the CD4 count at screening and the peak 
summed 85A peptide pool response (R=0.04, p=0.09), nor between HIV RNA load at 
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screening and the peak immune response (R= -0.04, p=0.08). There was a strong 
negative correlation between viral load at screening and the plateau immune response 
at week 24 (R= -0.8, p=0.002).  
Four subjects were found to have LTBI. However, there were no significant post-
vaccination changes in the magnitude of ESAT-6/CFP10 responses in these subjects 
(data not shown). 
Ag85A-specific cytokine/chemokine production by CD4+ T cells prior to MVA85A 
vaccination was undetectable and increased significantly post-vaccination (Fig. 4a). 
One week following MVA85A vaccination, more than 40% of Ag85A-specific CD4+ 
T cells produced IFN-γ, IL-2, MIP-1β and TNF-α  simultaneously (p<0.01); this 
remained significant at week 2 (p<0.05). By week 8 post-vaccination, 60% of Ag85A-
specific CD4+ T cells were still producing IFN-γ, IL-2 and TNF-α simultaneously; 
production of IL-2 and IFN-γ was maintained until 24 weeks. Production of MIP-1β 
was not detected beyond week 2 post-vaccination (Fig. 4a, 5a). In the first two weeks 
post-vaccination, Ag85A-specific CD4+ T cells exhibited similar functional profiles 
in the HIV-infected groups, both low dose and high dose, and the "control" low dose 
HIV-uninfected group; in all cases, the responses were dominated by four functionally 
distinct subsets (Fig. 4b, c). IFN-γ production measured by ICS correlated closely 
with IFN-γ secretion observed in the ELISpot assay (R= 0.75, p<0.0001, n=45; data 
not shown). 
Surface expression of the HIV M-tropic co-receptor CCR5 was monitored throughout 
the course of vaccination (Fig. 5). At week 1 post-vaccination, the MFI for CCR5 was 
highest in the activated Ag85A-specific CD4+ T cells, and lowest in the naïve CD4+ 
T cell subsets. Using the integrated MFI (iMFI) function calculated using both MFI 
and cell frequencies, expression of CCR5 was highest in the much larger memory 
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CD4+ T cell pool (Fig. 5d). No significant increase in CCR5 expression was detected 
in either the memory (Fig. 5e) or the total (Fig. 5f) CD4+ T cell populations as a 
result of MVA85A vaccination.  
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DISCUSSION 
This is the first Phase I trial of a subunit vectored TB vaccine in HIV-infected 
individuals. Similar studies in South Africa (Scriba et al, submitted) and Senegal 
(Mboup et al, unpublished data) are ongoing. The two main findings of this study are 
that MVA85A is safe in healthy subjects infected with HIV (a proportion of whom are 
co-infected with M. tuberculosis), and that MVA85A is immunogenic in this 
population, albeit at a lower level than in HIV-uninfected subjects.  
 
The local and systemic AE profiles in this trial were comparable to those observed in 
HIV-uninfected subjects previously. Whilst we have not evaluated the safety of this 
vaccine in HIV-infected subjects with lower CD4 counts, we would not expect the 
safety profile of this vaccine to be altered by progression of HIV disease. 
Importantly, there were no clinically significant effects of vaccination on either CD4 
count or HIV RNA load.  It is important to understand the variability in these 
parameters during stable untreated HIV infection, to enable meaningful 
interpretation of fluctuations throughout the trial period.  A recent quantitative 
review of cohort studies of HIV-infected adults suggests that, during stable 
untreated infection, intra-individual HIV RNA measurements can fluctuate over 
short periods of time by as much as 0.2-0.5 log10 copies/mL, with measurement 
error and physiological fluctuation each contributing about 50% of this variation. 
CD4 counts can also vary within patients by 60-130 cells/uL within weeks, but 
there is less measurement error, and during stable infection the overall within-
subject variation is proportionally larger for HIV RNA than for CD4 count 23. In 
this study, we also observed greater intra-individual variations in HIV RNA load 
compared to CD4 counts. Only one subject in each group demonstrated a more than 
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0.5 log rise in HIV RNA load at week 24 post-vaccination. The first of these (low 
dose group, 008) had displayed a relatively high baseline HIV RNA load and low 
baseline CD4 count at screening, just within the inclusion criteria. As the rise in HIV 
RNA load was only detectable 24 weeks after vaccination, it was considered highly 
unlikely that this was due to MVA85A vaccination. This subject commenced ARVs 
before week 24; all other subjects remained ARV-free throughout the trial period. The 
second subject (high dose group, 035) developed a rise in HIV RNA load between 
week 12 and week 24, peaking at just greater than a 0.5 log increase over baseline. 
However, this subject's HIV RNA load had been stable prior to this, so it was again 
deemed unlikely that this was a vaccination-related effect. Other fluctuations in the 
HIV RNA loads were observed, but any sustained rise was well within the expected 
0.5 log variation.  
HIV preferentially infects memory CD4+ T cells 24, 25, in particular HIV-specific 
memory CD4+ T cells, 20 and other activated antigen-specific CD4+ T cells 26. Using 
a sensitive qPCR method, we detected HIV gag DNA in Ag85A-specific CD4+ T 
cells from only 1/11 subjects post-vaccination (3 low dose and 8 high dose). This 
subject received high-dose MVA85A vaccination. This low positivity rate concurs 
with the stable CD4 count and HIV RNA load parameters in most subjects throughout 
the trial. Although the qPCR assay is sensitive, the low yield of Ag85A-specific 
CD4+ T cells entering the assay is an important limitation and provides just a 
snapshot of the HIV burden within the Ag85A-specific CD4+ T cell pool and 
warrants further future investigation. However, whilst small effects of MVA85A on 
HIV infection of CD4+ target cells cannot be excluded given the small sample size, 
these data suggest that MVA85A vaccination of healthy HIV-infected individuals 
does not lead to widespread preferential infection and depletion of vaccine-induced 
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CD4+ T cell populations in the periphery. These data are supported by no change in 
surface expression of the HIV co-receptor CCR5 following MVA85A vaccination. In 
addition, the lack of effect of vaccination on chemokine and cytokine levels in 
unstimulated serum supports the interpretation that vaccination with MVA85A did not 
lead to widespread immune activation in this subject group.  
 
We have shown that vaccine-induced immunogenicity, while of moderate magnitude, 
is significantly lower than in healthy HIV-uninfected subjects given the same dose of 
MVA85A. Thus, additional strategies may be required to augment immune responses 
to MVA85A vaccination in the context of HIV infection. Partial reconstitution of the 
immune system with ARVs may improve the response to vaccination. Indeed, this 
study shows that the baseline HIV RNA level is a strong negative predictor of 
summed 85A peptide pool responses at week 24 post-vaccination. In addition, a 
booster vaccination with MVA85A may be required to enhance the vaccine-induced 
immune response. 
 
The functional profile of Ag85A-specific CD4+ T cells observed in this study was 
remarkably comparable to that of healthy HIV-uninfected subjects 19 and M. 
tuberculosis-infected subjects 10, although the response in HIV-infected subjects is 
less durable. IFN-γ and TNF-α are known to be important for protective immunity to 
TB, and these cytokines dominated the MVA85A vaccine-induced CD4+ T cell 
response elicited in the current study cohort. In this study, production of MIP-1β by 
Ag85A-specific CD4+ T cells was not detectable after week 2 post-vaccination. The 
production of multiple cytokines including IL-2 and MIP-1β by HIV-specific CD8+ T 
cells is associated with long-term non-progression, albeit with uncertain causality27.  
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The production of β-chemokines by CD8+ T cells was not assessed here as there were 
no detectable Ag-85A specific CD8+ T cell responses pre- or post-vaccination.  
 
 Vaccine-induced bystander activation of CD4+ T cells in HIV-infected subjects is 
likely to be undesirable because activated CD4+ T cells are at increased risk of HIV 
infection. The overall pattern of cytokine production and the frequency of CMV-
specific CD4+ T cell producing cytokines remained both relatively stable over the 24-
week period following MVA85A vaccination, and comparable to pre-vaccination 
responses (Supplemental Figure 1).  These data suggest that MVA85A vaccination 
does not induce substantial bystander activation of antigen-specific CD4+ T cell 
populations. 
 
Demonstrating the safety and immunogenicity of a new TB vaccine in an important 
target population is a crucial step, but does not mean that the vaccine will be effective. 
However, the data presented here support further safety and immunogenicity studies 
of this candidate vaccine, together with proof-of-concept efficacy trials, in TB and 
HIV endemic areas.  
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TABLE and FIGURE LEGENDS 
 
Table 1 Subject demographics: Comparison of low and high dose vaccination groups.  
 
Tables 2a and b Local and systemic adverse events: Comparison of low and high 
dose vaccination groups with dose-matched HIV-uninfected subjects from previous 
trials of MVA85A. There were significantly fewer systemic AEs per person, (and a 
lower frequency of systemic AEs overall,) in the 10 HIV-infected subjects receiving 
high dose MVA85A compared with HIV-uninfected subjects receiving the same dose 
of vaccine (p=0.026, data not shown and Pathan et al, unpublished) 
 
Table 3a Ex-vivo IFN-γ ELISpot statistics (1): Comparison of screening, week 1 and 
week 24 responses within low and high dose groups, for both summed and single 
pooled peptides, using Wilcoxon signed rank test. Median (range), median difference 
(range, of week 1 and week 24 responses compared to screening,) and p-values are 
shown. 
 
Table 3b Ex-vivo IFN-γ ELISpot statistics (2): Comparison of responses between 
HIV-infected and HIV-uninfected subjects, at each time-point and each vaccine dose, 
using Mann-Whitney U test. Median (range), difference in medians (with 95% 
confidence intervals), and p-values are shown. AUC analysis is also shown. 
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Figure 1 CONSORT diagram. Follow-up was conducted for 24 weeks post-
vaccination in both the low dose MVA85A (5x107pfu; left panels) and high dose 
MVA85A (1x108 pfu; right panels) groups. Of the volunteers excluded at screening, 
5/15 had CD4 counts <350 x 106/L and/or exhibited progressively decreasing CD4 
counts, 2/15 had HIV RNA loads of >100,000 copies/mL, 2/15 had abnormal chest 
radiographs, 1/15 had a current history of active eczema, and 1/15 had a history of 
illicit drug usage and unstable depression; the remaining 4/15 were eligible but failed 
to attend for vaccination (2 in each dose group).  
 
Figure 2 (a-d) Comparison of pre and post-vaccination CD4 counts: Longitudinal 
CD4 counts of subjects in the low dose (5x107 pfu MVA85A) group pre-vaccination, 
(a); and high dose (1x108 pfu MVA85A) group (c) pre-vaccination. Longitudinal CD4 
counts post-vaccination (up to 24 weeks) in the low dose (b) and high dose (d) 
groups. NB X-axis for the pre-vaccination data is not standardised for time but varies 
from 1-6 years depending on the individual subject.(e-h) Comparison of pre and post-
vaccination HIV RNA loads: Longitudinal HIV RNA loads of subjects in the low dose 
(e) and high dose (g) groups pre-vaccination. Longitudinal HIV RNA loads post-
vaccination (up to 24 weeks) in the low dose (f) and high dose (h) groups. 
Anonymous number codes (001-036) shown in key. NB X-axis for the pre-
vaccination data is not standardised for time but varies from 1-6 years depending on 
the individual subject. 
 
Figure 3 (a-d) IFN-γ ELISpot responses in the low dose and high dose groups. 
Longitudinal responses to the single 85A peptide pool are shown for the low dose 
(5x107 pfu MVA85A) group, (a) and high dose (1x108 pfu MVA85A) group (b). 
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Longitudinal responses to the summed 85A peptide pools are shown for the low dose 
(c) and high dose (d) groups. Horizontal bars represent the median response.  
Comparison of IFN-γ ELISpot responses in HIV-infected and HIV-uninfected subjects 
(e-g). Responses to summed 85A peptide pools for low dose and high dose vaccine 
regimes at screening (e); week 1 post-vaccination (f) and week 24 post-vaccination 
(g).  Subjects with LTBI are denoted with grey symbols. Statistically significant 
differences in the responses between HIV-infected and HIV-uninfected subjects were 
assessed using the Mann-Whitney U test. *p<0.05; **p<0.01; ***p<0.001. Horizontal 
bars represent the median response.  
 
Figure 4 MVA85A induces polyfunctional Ag85A-specific CD4+ T cells in HIV-
infected individuals. MVA85A vaccination-induced production of IFN-γ, IL-2, MIP-
1β and TNF-α by antigen-specific CD4+ T cells was assessed following Ag85A 
peptide stimulation of cryopreserved PBMC using polychromatic flow cytometry. (a) 
Individual data points are shown with median line, interquartile range (open bars) and 
range (whiskers) at baseline and at each time-point post-vaccination for every 
possible combination of cytokine/chemokine production. High dose and low dose 
groups were analyzed together (n=17). (b) The functional profile of the Ag85A-
specific CD4+ T cell response is summarized in the pie charts (n=17). CD4+ T cells 
producing a given number of cytokines/chemokines are grouped and colour-coded 
together. Pie charts are shown for the high dose HIV-infected group (n=9), the low 
dose HIV-infected group (n=8) and low dose healthy controls (n=6). (c) Absolute 
percentages of the highest frequencyCD4+ T cell subsets producing specific 
combinations of chemokine/cytokines at week 1 post-vaccination across the different 
groups; * p<0.05, ** p<0.01. 
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Figure 5 Cytokine/chemokine production and receptor expression 
(a) Absolute percent of Ag85A-specific CD4+ T cells producing IL-2 or MIP-1β at 
week 1 post-MVA85A vaccination in HIV-infected subjects (low dose and high dose, 
n=17) versus healthy controls (n=6). Representative histogram (b) and scatter plot (c) 
showing CCR5 median fluorescence intensity (MFI) in naïve CD4+ T cells, memory 
CD4+ T cells and activated Ag85A-specific CD4+ T cells at  week 1 post- 
vaccination (n=16 in all groups). (d) Scatter plot showing CCR5 integrated MFI 
(iMFI) for naïve, memory and Ag85A-specific CD4+ T cells (n=16). Line charts 
showing CCR5 MFI in memory CD4+ T cells (e) and the total CD4+ T cell 
population (f) across the MVA85A vaccination time-course (n=16). * p<0.05, ** 
p<0.01. 
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TABLE 1 
Demographics and screening results Low dose 
5x10
7
pfu 
High dose 
1x10
8
pfu 
Sex Male 
Female 
9 (90%) 
1 (10%) 
8 (80%) 
2 (20%) 
Median age (range) 35.8 (21-52) 35.1 (27-46) 
Continent of Birth Africa 
Asia 
Europe 
North America 
South America 
 
4 (40%) 
0 
4 (40%) 
1 (10%) 
1 (10%) 
 
4 (40%) 
1 (10%) 
5(40%) 
0 
0 
 
BCG Definite 
Uncertain 
7 (70%) 
3 (30%) 
10 (100%) 
0 (0%) 
Latent infection (ESAT-6/CFP-10 +) 2 (20%) 3 (30%) 
Median CD4 count (range) 570  
(430-1200) 
625  
(410-840) 
   
   
Median HIV RNA load (range) 6069 (39-
41890) 
14805 (49-
71090) 
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TABLE 2 
(a) 
Local Adverse Events 
  
HIV-infected 
 
HIV-negative 
Dose 
Number of subjects 
5x10
7
pfu 
n=10 
1x10
8
pfu 
n=10 
5x10
7
pfu 
n=43 
1x10
8pfu 
n=12 
Redness 10 (100%) 10 (100%) 42 (98%) 12 (100%) 
Pruritis 10 (100%) 9 (90%) 22 (51%) 8 (67%) 
Pain 8 (80%) 7 (70%) 36 (84%) 12 (100%) 
Induration 10 (100%) 10 (100%) 42 (98%) 12 (100%) 
 
(b) 
Systemic Adverse Events 
  
HIV-infected 
 
HIV-negative 
Dose 
Number of subjects 
5x10
7
pfu 
n=10 
1x10
8
pfu 
n=10 
5x10
7
pfu 
n=43 
1x10
8
pfu 
n=12 
Measured fever 1 (10%) 0 (0%) 3 (7%) 5 (42%) 
Subjective fever 3 (30%) 2 (20%) 17 (40%) 9 (75%) 
Arthralgia 2 (20%) 3 (30%) 6 (14%) 7 (58%) 
Headache 6 (60%) 4 (40%) 21 (49%) 10 (83%) 
Myalgia 1 (10%) 2 (20%) 18 (42%) 9 (75%) 
Nausea 1 (10%) 0 (0%) 4 (9%) 4 (33%) 
Vasovagal syncope 0 (0%) 1 (10%) 0 (0%) 0 (0%) 
Axillary lymphadenopathy 1 (10%) 0 (0%) 2 (5%) 2 (17%) 
Change in 
haematology/biochemistry 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deleted: F
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TABLE 3 
 
(a)  
Summed pooled peptides – within dose changes from screening to peak and plateau 
 
Dose  Screening 
(n=10) 
Week 1 
(n=10) 
Week 24 
(n=10) 
Median (range) 10 (3, 20) 738 (109, 4398) 20 (0, 237) n=9 
Median difference (range) (compared to screening)  730 (109, 4383) 
 
17 (-8, 218) 
n=9 
Low 
p-value*  0.007 0.17 
Median (range) 3 (0, 14) 1730 (758, 2138) 42 (33, 256) 
Median difference (range) (compared to screening)  1721 (743, 2135) 42 (27, 247) 
High 
p-value*  0.005 0.007 
*Wilcoxon signed rank test 
 
Single pooled peptides – within dose changes from screening to peak and plateau 
 
Dose  Screening 
(n=10) 
Week 1 
(n=10) 
Week 24 
(n=10) 
Median (range) 0 (0, 8) n=9 393 (67, 1275) n=9 13 (2, 103) n=9 
Median difference (range) (compared to screening)  393 (60, 1272) 
n=9 
13 (2, 97) 
n=9 
Low 
p-value*  0.009 0.032 
Median (range) 0 (0, 8) 502 (312, 677) 14 (0, 68) 
Median difference (range) (compared to screening)  502 (294, 677) 14 (0, 66) 
High 
p-value*  0.005 0.048 
*Wilcoxon signed rank test 
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(b) 
 
HIV-infected vs. HIV-negative group 
 Summed Pooled peptides Median (range) HIV+ 
 
Median (range) HIV- 
 
Difference in medians 
(95% confidence interval) 
p-value* 
Low dose 738 
(109, 4398) 
n=10 
2147 
(1173, 5085) 
n=21 
1101 
(-393, 2873) 
0.12 Week 1 
High dose 1730 
(758, 2138) 
n=10 
6493 
(4854, 7312) 
n=12 
4557 
(3038, 5904) 
0.0001 
Low dose 20 
(0, 237) 
n=9 
385 
(228, 1010) 
n=20 
339 
(161, 534) 
0.004 Week 24 
High dose 42 
(33, 256) 
n=10 
970 
(655, 1199) 
n=12 
820 
(569, 1050) 
0.0001 
Low dose 2162 
(519, 23348) 
n=9 
16317 
(9129, 36418) 
n=20 
11884 
(3191, 17387) 
0.02 Area under the curve 
High dose 5929 
(3167, 11607) 
n=10 
41575 
(26919, 53807) 
n=12 
31384 
(20778, 45504) 
0.0001 
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Assessed for eligibility
(n=20)
Allocated to BCG-MVA 85A
(5x107 pfu) (n=10)
Received allocated intervention
(n=10)
Lost to follow-up (n=0)
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Analysis (n=10)
Excluded (n=10)
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Allocated to BCG-MVA 85A
(1x108 pfu) (n=10)
Received allocated intervention
(n=10)
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Analysis (n=10)
Withdrew (n=0)
Figure 1
Assessed for eligibility
(n=15)
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ABSTRACT 
OBJECTIVES: Control of the TB epidemic is a global health priority and one that is 
only likely to be achieved through vaccination. The critical overlap with the HIV 
epidemic requires any effective TB vaccine regimen to be safe in individuals who are 
infected with HIV. The objectives of this clinical trial were to evaluate the safety and 
immunogenicity of a leading candidate TB vaccine, MVA85A, in healthy, HIV-
infected adults. 
DESIGN: This was an open-label Phase I trial, performed in 20 healthy HIV-
infected, antiretroviral-naïve subjects. Two different doses of MVA85A were each 
evaluated as a single immunisation in 10 subjects, with 24 weeks of follow-up.  Safety 
of MVA85A was assessed by clinical and laboratory markers, including regular CD4 
counts and HIV RNA load measurements. Vaccine immunogenicity was assessed by 
ex-vivo IFN-γ ELISpot assays and flow cytometric analysis. 
RESULTS: MVA85A was safe in subjects with HIV infection, with an adverse event 
profile comparable to historical data from previous trials in HIV-uninfected subjects. 
There were no clinically significant vaccine-related changes in CD4 count or HIV 
RNA load in any subjects, and no evidence from qPCR analyses to indicate that 
MVA85A vaccination leads to widespread preferential infection of vaccine-induced 
CD4+ T cell populations. Both doses of MVA85A induced an antigen-specific IFN-γ 
response that was durable for 24 weeks, although of a lesser magnitude compared to 
historical data from HIV-uninfected subjects. The functional quality of the vaccine-
induced T cell response in HIV-infected subjects was remarkably comparable to that 
observed in healthy HIV-uninfected controls, but less durable. 
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CONCLUSION: MVA85A is safe and immunogenic in healthy adults infected with 
HIV. Further safety and efficacy evaluation of this candidate vaccine in TB and HIV 
endemic areas is  merited.  
 
ARTICLE SUMMARY SECTION 
Article focus 
• HIV infection increases susceptibility to TB, and globally, TB is the cause of 
death in up to half of AIDS deaths 
• There is an urgent need for a safe and effective TB vaccine in HIV-infected 
people 
Key messages 
• MVA85A, a leading candidate TB vaccine, is safe and well tolerated  in HIV-
infected people and does not induce changes in either CD4 count or HIV RNA 
load 
• MVA85A is immunogenic in HIV-inf cted people, and induces a similar 
immune profile to that seen in HIV-uninfected people, but the immunogenicity 
is less durable in HIV-infected people.  
Strengths and limitations of this study 
• This is a Phase I study with 20 subjects, and further studies are needed in TB 
endemic countries in this important target population.  
 
 
Funding: This study was supported by The Wellcome Trust (Grant number 
WT076943MA), TBVAC (an EU 6th Framework programme grant) and The NIHR 
Oxford Biomedical Research Centre.  
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INTRODUCTION 
Tuberculosis (TB) and Human Immune Deficiency Virus (HIV) are inextricably 
linked. At the end of 2007, approximately 33.2 million persons were living with HIV-
1 infection, an estimated one-third of whom were co-infected with Mycobacterium 
tuberculosis (M. tuberculosis)1. TB is the cause of death for up to half of all AIDS 
patients2  and the increasing incidence of drug-resistant strains of M. tuberculosis 
poses a significant threat to a susceptible HIV-infected population 3. 
Mycobacterium bovis (M. bovis) Bacille Calmette Guérin (BCG) fails to  protect 
consistently against the adult pulmonary form of TB, whilst providing reliable 
protection against disseminated infection in childhood 4. An improved vaccine 
strategy is thus essential for global control of this disease 5. MVA85A (modified 
vaccinia virus Ankara expressing antigen 85A) is a leading candidate TB vaccine, 
designed to enhance the effect of BCG; it is safe and highly immunogenic in healthy 
BCG-naïve and BCG-vaccinated subjects, and in subjects latently infected with M. 
tuberculosis in the UK and Africa6-11.  
It is essential that any new TB vaccine is safe in an HIV-infected population. Subunit 
vaccines are an ideal choice for an immuno-compromised population in which the 
safety of replicating whole organism vaccines may be a concern. Although MVA is a 
live viral vaccine vector, it cannot replicate in human cells 12, 13. There are now safety 
data from a number of clinical trials with recombinant MVAs in HIV-infected 
subjects, which demonstrate no sustained effect on either HIV   load or CD4 count14-
16
. Most of these studies assessed immune-reconstituted HIV-infected individuals on 
anti-retroviral therapy (ARV); however, some ARV-naïve subjects with more 
advanced HIV infection have also been vaccinated with a recombinant MVA, with no 
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significant rise in HIV load or fall in CD4 count over a 4-week follow-up period 17. 
Preclinical studies in severely immuno-suppressed macaques have also documented 
safety in this model 18. To date, MVA85A has been administered to more than 1,000 
individuals with no vaccine-related serious adverse events 6, 8-11 (McShane, 
unpublished data).  
Here we present the first clinical trial of a subunit TB vaccine in an HIV-infected 
population. The primary endpoint was to evaluate the safety of two doses of 
MVA85A in healthy HIV-infected subjects in the UK and the secondary endpoint was 
to evaluate the immunogenicity of this vaccine regimen. .  
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METHODS 
Trial design and participants 
The protocol for this multi-site study was approved by the Medicines and Healthcare 
products Regulatory Agency (MHRA) and ethical approval was obtained from the 
Gene Therapy Advisory Committee (GTAC). Participants were recruited from the 
Genitourinary Medicine (GUM) departments at the Oxford Radcliffe Hospitals NHS 
Trust, University Hospitals Birmingham NHS Foundation Trust (Selly Oak Hospital), 
Great Western Hospitals NHS Foundation Trust, and Imperial College Healthcare 
NHS Trust, London.  
Potentially eligible subjects were referred to the clinical trial team. Vaccination visits 
took place in Oxford; screening and follow-up visits took place at local NHS Trust 
sites. Written informed consent was obtained from all subjects prior to enrolment in 
the trial, and the referring HIV physicians were notified.  
Eligibility required participants to be generally healthy, aged 18-55 years, with a 
normal chest radiograph and no clinical or radiological evidence of TB disease, a 
current CD4 count (measured at screening) of at least 350x106/L, a nadir CD4 count 
of not less than 300x106/L and an HIV RNA load at screening of less than 100,000 
copies/mL. All subjects were diagnosed with HIV infection at least six months before 
screening and had not received any ARVs within the preceding six months (full 
inclusion/exclusion criteria, Table 1). In all cases, testing for latent M. tuberculosis 
infection (LTBI) was conducted at screening using an in-house ex-vivo interferon 
gamma (IFN-γ) ELISpot assay for ESAT6 and CFP10 peptides. Subjects found to be 
latently infected were referred back to their consultants for possible treatment at the 
end of the trial.  
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The trial was registered on a clinical trials database: ClinicalTrials.gov ID 
NCT00395720. 
Vaccine 
Clinical grade MVA was produced under Good Manufacturing Practice standard by 
IDT Biologika GmbH. 
Procedures  
The first group of 10 subjects  were vaccinated intradermally with MVA85A at a dose 
of 5x107 plaque-forming units (pfu); the second group of 10 subjects were 
subsequently vaccinated with a dose of 1 x 108pfu MVA85A. Subjects were 
sequentially allocated first to the low dose group and then once safety had been 
demonstrated, to the high dose group. A diary card was completed by all subjects 
recording local and systemic adverse events and body temperature for days 1 to 7 
post-vaccination. All subjects were followed up regularly for 12 months; blood 
samples taken at each time-point for CD4 count, HIV RNA load measurement and 
cellular immunological assays. CD4 count and HIV RNA load results were 
communicated to the patient’s HIV physician at regular intervals. Routine 
haematology and biochemistry assays were performed at weeks 1 and 12 after 
vaccination. All subjects attended their usual NHS follow-up appointments and 
received routine clinical care throughout the trial.  
 
Immunological assays 
Ex vivo IFN-γ ELISpot assays were performed at screening and at weeks 1, 2, 4, 12, 
and 24 post-vaccination using fresh peripheral blood mononuclear cells (PBMCs), as 
described previously 10. A single pool of 15-mer peptides spanning the Ag85A protein 
(66, overlapping by 10 amino acids, 2µg/mL final concentration of each peptide in 
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each well),  and 7 pools of non-overlapping 9-10 Ag85A peptides (final concentration 
of 10µg/mL in each well) were used to stimulate for the IFN-γ ELISpot assays. For 
the 7 peptide pool wells, the results were summed across all peptide pools for each 
time-point. This potentially resulted in duplicate counting of T cells that responded to 
any of the 10mer overlap regions, since any 10mer occurred in two pools with 
adjacent peptides, but allows direct comparison with immunogenicity data from 
previous trials.  
Intracellular cytokine staining of PBMCs was performed as described previously 19. 
Briefly, cells were stained with the amine reactive LIVE/DEAD fixable dye ViViD 
(Molecular Probes, Invitrogen) and then surface stained with monoclonal antibodies 
against CD4, CD14, CD19, CD27, CD45RO, CD57 and CCR5. After washing, cells 
were permeabilized (Cytofix/cytoperm kit; BD Pharmingen) and stained 
intracellularly for CD3, CD8, IFN-γ, TNF-α, IL-2 and MIP-1β. Naïve CD4+ memory 
cells were identified as CD45RO-CD27+CD57+; memory CD4 T cell as 
CD45RO+CD27±CD57±. CD4+ T cells producing two or more cytokines (IFN-γ, IL-
2 or TNF-α) following stimulation with Ag85A peptides were sorted to greater than 
98% purity using a modifed FACSAria flow cytometer (BD Biosciences); CMV-
specific CD4+ T cells, defined similarly, and bulk resting memory CD4+ T cells were 
sorted simultaneously Cytokine production and the expression of surface markers 
were analysed using FlowJo version 8.7 (Tree Star Inc), Pestle version 1.5 and SPICE 
version 4.1 (both from Mario Roederer, Vaccine Research Center, NIAID, NIH, 
USA). 
Real-time quantitative PCR (qPCR) was used to determine the proportion of HIV-
infected Ag85A-specific CD4+ T cells; resting memory CD4+ T cells (non-Ag85A-
specific) and CMV-specific CD4+ T cells were used as intra-individual controls. 
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HIV-1 gag proviral DNA within sorted CD4+ T cell populations was quantified by 
qPCR, as described previously 20. qPCR was performed simultaneously for albumin 
gene copy number in all sorted CD4+ T cell populations to quantify cell number in 
each reaction. HIV-1 gag primers for qPCR: Gag clade B primer position and 
sequence were 795gagB-F: ggtgcgagagcgtcagtattaag, 911gagB-R: 
agctccctgcttgcccata, and probe was 841gagB-P: FAM-aaaattcggttaaggccagggggaagaa-
QSY7 (MegaBases). Gag clade C primer position and sequence were 689gagC-F: 
ggggaagtgaYatagcagga, 841gagC-R: ggYccttgtYttatgtccaa, and probe was 710gagC-
P: ctactagtaVccttcaRgaacaRataRcatggatga. Albumin primer sequences were Alb-F: 
tgcatgagaaaacgccagtaa, Alb-R: atggtcgcctgttcaccaa, and probe: Alb-P: FAM-
tgacagagtcaccaaatgctgcacagaa-QSY7. Degenerate HIV gag clade A/G primer position 
and sequence were 783gagA/G-F: 5’-gagagagatgggtgcgagagcgtc-3’ 
(GAGAGAGATGGGTGCGAGAGCGTC), 895gagA/G-R: 5’-
ctttccagctccctgcttgccca-3’, and probe was 844gagA/G-P: 5’-
attcggttaaggccagggggaaagaaaaaat-3’. 
 
 
 
CD4+ T cells from 12 subjects (4/10 in the low-dose group and 8/10 in the high-dose 
group) were analysed for HIV gag content; low sort yields(less than 250 antigen-
specific CD4+T cells) prevented similar analyses in the remaining 8 subjects.  
Serum levels of MIP-1α, MIP-1β, RANTES, TNF-α and IL-2 were measured pre-
vaccination and at weeks one, two and 24 post-vaccination using FlowCytomix 
simplex kits (Bender MedSystems). Serum was thawed and plated out in duplicate in  
round-bottom 96-well plates. Samples were used neat for MIP-1α, MIP-1β, TNF-α 
and IL-2, and diluted 1/10 for RANTES. Standards (provided) were reconstituted as 
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specified, and 1/3 serial dilutions plated in duplicate. Bead and biotin-conjugate 
cocktails were added to each well in 25µL and 50µL volumes, respectively, and 
incubated for two hours in the dark at room temperature. Samples were then washed 
twice in 100µL Assay Buffer. Streptavidin-PE (50µL) and Assay Buffer (100µL) were 
added and plates were incubated for one hour in the dark at room temperature. 
Samples were then washed again and transferred to cluster tubes in  4% 
paraformaldehyde in PBS (400uL) and acquired using an LSRII flow cytometer (BD 
Biosciences) set up with the beads provided and the highest concentration standard;.  
the stopping gate was set so that at least 300 events were collected for each sample. 
Data were analysed using FlowCytomixPro software (Bender MedSystems). 
 
Statistical analysis 
Continuous outcomes were presented as a median (range) for each group. Median 
difference was calculated to assess difference between two groups and the 
corresponding 95% confidence interval was computed using the robust method 
proposed by Newson21. The overall magnitude of vaccine-induced CD4+ T cell 
responses over the 24 weeks was summarised using area under the curve (AUC) for 
each dose group. Peak (1 week) and plateau (24 weeks) CD4+ T cell responses were 
compared with those at baseline (pre-vaccination) using the Wilcoxon signed rank 
test, Stata Statistical Software, Release 9.0. 2005 (Stata Corporation, College Station, 
TX). Mann-Whitney U test was used to compare between the vaccine groups. 
Comparisons between specific time points in this trial and previously published trials 
of MVA85A6, 22, and between low and high dose groups were conducted using the 
Mann-Whitney U test (Stata). 
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Non-parametric Spearman rank analyses were used to correlate immune assays and 
CD4/HIV RNA load with CD4+ T cell responses. 
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RESULTS 
Thirty-five individuals attended for screening between October 2006 and June 2009; 
20 subjects were enrolled (Fig. 1, Flowchart). The demographics of the 20 
participants are shown in Table 2, and were comparable across the two groups.  
 
Safety of MVA85A in HIV-infected subjects 
Local reactions related to the MVA vaccine occur during the first week after 
vaccination and have been reported previously 6, 7, 10. The local adverse event (AE) 
profile recorded in the diary cards of the HIV-infected subjects in this study was 
comparable to that observed in HIV-uninfected subjects6, 7, 10 (Pathan et al, 
unpublished data), although pruritis appeared slightly higher in the HIV-infected 
group (Table 3a). There were no severe local reactions and most local AEs were mild.  
 
One subject in the low dose group experienced a single episode of fever greater than 
37.5 oC (documented at 38.1oC). All other subjective systemic symptoms occurred 
with similar frequencies in the low dose and high dose groups (Table 3b). There was 
one moderate systemic AE and all others were mild.   
 
Pre-vaccination CD4 counts and HIV RNA loads for all 20 subjects over a time 
period of one to six years before enrolment are shown in Figure 2. These longitudinal 
data illustrate the levels of natural fluctuation that occur over time and represent 
important baseline measurements for the interpretation of these parameters post-
vaccination, also shown in Figure 2, in the absence of an unvaccinated control group. 
No clinically significant changes in CD4 counts or HIV RNA load was seen post-
vaccination.  
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A major concern with respect to the vaccination of HIV-infected individuals is the 
possibility that responding antigen-specific CD4+ T cells will act as preferential 
targets for HIV infection as a function of their activated status, thereby enhancing the 
propagation of HIV and accelerating disease progression. In this study, however, there 
was no evidence for preferential HIV infection of Ag85A-specific CD4+ T cells. The 
median number of CD4+ T cells in Ag85A-specific qPCR reactions was 73 (95% CI: 
15-130 CD4+ T cells). Where possible, multiple time-points throughout the 
vaccination course for each subject were analyzed, to determine the proportion of 
Ag85A-specific CD4+ T cells that were infected with HIV. Of 29 Ag85A-specific 
CD4+ T cell samples in total (11 subjects), only one subject showed a positive signal 
for HIV gag DNA by qPCR at two different post-vaccination timepoints (weeks 2 and 
8 post-vaccination; data not shown). In the 11 subjects tested, resting HIV-specific 
and CMV-specific memory cell populations showed a positive signal in all assays 
(data not shown). In addition, vaccination had no effect on levels of MIP-1α, MIP-1β, 
RANTES, TNF-α and IL-2 in unstimulated serum (data not shown).  
 
Immunogenicity of MVA85A in HIV-infected subjects 
MVA85A induced significant antigen-specific T cell responses as measured by IFN-γ 
ELISpot assay (Fig. 3a-d, Table 4a). In the low dose group, the frequency of IFN-γ-
secreting T cells responding to the single 85A peptide pool at week one post-
vaccination, increased by a median of 393 sfc/million compared to prevaccination 
baseline measured on the day of screening (p=0.009); there a significant increase 
remained until 24 weeks post-vaccination (p=0.032). In the high dose group, a median 
increase of 502 sfc/million was apparent at week 1 post-vaccination (p=0.005); again, 
this response was maintained until 24 weeks (p=0.048). In both groups, T cell 
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responses to the summed 85A peptide pools followed a similar pattern with a 
significant increase above baseline at week 1 (738 and 1730 sfc/million for low and 
high dose groups, respectively), although, the week 24 response was only maintained 
significantly above baseline in the high dose group (low dose p=0.17; high dose 
p=0.007). There were no significant differences in the overall magnitude (i.e. AUC) 
of the IFN-γ response between low and high dose groups across the follow-up period 
(p=0.29 and p=0.68 for summed and single peptide pools, respectively; data not 
shown). However the responder rate was higher in the high dose group with no 
observed non-responders (ie those subjects with no measurable vaccine induced 
immune response) compar d with 1-2 non-responders (depending on antigen) in the 
low dose group. Overall, the kinetics of the Ag85A-specific T cell responses were 
very similar to those previously reported in similar studies of HIV-uninfected subjects 
6-11
. 
Ag85A-specific T cell responses in the low-dose group were significantly lower 
compared to those observed in previously published studies of HIV-uninfected 
subjects (AUC analysis, p=0.02; Table 4b)6, 22. This difference was not significant at 
week 1 (MWU analysis, p=0.12), which represents the peak response, but was 
significant at week 24 post-vaccination (MWU analysis, p=0.004; Table 4b, Figure 
3e-g). There were no significant differences in baseline (pre-vaccination) responses 
between the HIV-infected and HIV-uninfected groups (MWU analysis, p=0.85; 
Figure 3e). Similarly, HIV-infected subjects in the high dose group exhibited 
significantly lower responses compared to HIV-uninfected subjects who received the 
same dose of MVA85A (AUC analysis, p=0.0001; week 1 and week 24 MWU 
analysis, p = 0.0001; Table 4b, Figure 4e-g). Again, baseline responses were 
comparable (p=0.24) (Fig. 3e).  
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There was no significant correlation between the CD4 count at screening and the peak 
summed 85A peptide pool response (R=0.04, p=0.09), nor between HIV RNA load at 
screening and the peak immune response (R= -0.04, p=0.08). There was a strong 
negative correlation between viral load at screening and the plateau immune response 
at week 24 (R= -0.8, p=0.002).  
Four subjects were found to have LTBI. However, there were no significant post-
vaccination changes in the magnitude of ESAT-6/CFP10 responses in these subjects 
(data not shown). 
Ag85A-specific cytokine/chemokine production by CD4+ T cells prior to MVA85A 
vaccination was undetectable and increased significantly post-vaccination (Fig. 4a). 
One week following MVA85A vaccination, more than 40% of Ag85A-specific CD4+ 
T cells produced IFN-γ, IL-2, MIP-1β and TNF-α  simultaneously (p<0.01); this 
remained significant at week 2 (p<0.05). By week 8 post-vaccination, 60% of Ag85A-
specific CD4+ T cells were still producing IFN-γ, IL-2 and TNF-α simultaneously; 
production of IL-2 and IFN-γ was maintained until 24 weeks. Production of MIP-1β 
was not detected beyond week 2 post-vaccination (Fig. 4a, 5a). In the first two weeks 
post-vaccination, Ag85A-specific CD4+ T cells exhibited similar functional profiles 
in the HIV-infected groups, both low dose and high dose, and the "control" low dose 
HIV-uninfected group; in all cases, the responses were dominated by four functionally 
distinct subsets (Fig. 4b, c). IFN-γ production measured by ICS correlated closely 
with IFN-γ secretion observed in the ELISpot assay (R= 0.75, p<0.0001, n=45; data 
not shown). 
Surface expression of the HIV M-tropic co-receptor CCR5 was monitored throughout 
the course of vaccination (Fig. 5). At week 1 post-vaccination, the MFI for CCR5 was 
highest in the activated Ag85A-specific CD4+ T cells, and lowest in the naïve CD4+ 
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T cell subsets. Using the integrated MFI (iMFI) function calculated using both MFI 
and cell frequencies, expression of CCR5 was highest in the much larger memory 
CD4+ T cell pool (Fig. 5d). No significant increase in CCR5 expression was detected 
in either the memory (Fig. 5e) or the total (Fig. 5f) CD4+ T cell populations as a 
result of MVA85A vaccination.  
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DISCUSSION 
This is the first Phase I trial of a subunit vectored TB vaccine in HIV-infected 
individuals. The two main findings of this study are that MVA85A is safe in healthy 
subjects infected with HIV (a proportion of whom are co-infected with M. 
tuberculosis), and that MVA85A is immunogenic in this population, albeit at a lower 
level than in HIV-uninfected subjects. As a result of these promising findings, Similar 
studies in South Africa (Scriba et al, submitted) and Senegal (Mboup et al, 
unpublished data) are ongoing. 
 
The local and systemic AE profiles in this trial were comparable to those observed in 
HIV-uninfected subjects previously. Whilst we have not evaluated the safety of this 
vaccine in HIV-infected subjects with lower CD4 counts, we would not expect the 
safety profile of this vaccine to be altered by progression of HIV disease. 
Importantly, there were no clinically significant effects of vaccination on either CD4 
count or HIV RNA load.  It is important to understand the variability in these 
parameters during stable untreated HIV infection, to enable meaningful interpretation 
of fluctuations throughout the trial period.  A recent quantitative review of cohort 
studies of HIV-infected adults suggests that, during stable untreated infection, intra-
individual HIV RNA measurements can fluctuate over short periods of time by as 
much as 0.2-0.5 log10 copies/mL, with measurement error and physiological 
fluctuation each contributing about 50% of this variation. CD4 counts can also vary 
within patients by 60-130 cells/uL within weeks, but there is less measurement error, 
and during stable infection the overall within-subject variation is proportionally larger 
for HIV RNA than for CD4 count 23. In this study, we also observed greater intra-
individual variations in HIV RNA load compared to CD4 counts. Only one subject in 
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each group demonstrated a more than 0.5 log rise in HIV RNA load at week 24 post-
vaccination. The first of these (low dose group, 008) had displayed a relatively high 
baseline HIV RNA load and low baseline CD4 count at screening, just within the 
inclusion criteria. As the rise in HIV RNA load was only detectable 24 weeks after 
vaccination, it was considered highly unlikely that this was due to MVA85A 
vaccination. This subject commenced ARVs before week 24; all other subjects 
remained ARV-free throughout the trial period. The second subject (high dose group, 
035) developed a rise in HIV RNA load between week 12 and week 24, peaking at 
just greater than a 0.5 log increase over baseline. However, this subject's HIV RNA 
load had been stable prior to this, so it was again deemed unlikely that this was a 
vaccination-related effect. Other fluctuations in the HIV RNA loads were observed, 
but any sustained rise was well within the expected 0.5 log variation.  
HIV preferentially infects memory CD4+ T cells 24, 25, in particular HIV-specific 
memory CD4+ T cells, 20 and other activated antigen-specific CD4+ T cells 26. Using 
a sensitive qPCR method, we detected HIV gag DNA in Ag85A-specific CD4+ T 
cells from only 1/11 subjects post-vaccination (3 low dose and 8 high dose). This 
subject received high-dose MVA85A vaccination. This low positivity rate concurs 
with the stable CD4 count and HIV RNA load parameters in most subjects throughout 
the trial. Although the qPCR assay is sensitive, the low yield of Ag85A-specific 
CD4+ T cells entering the assay is an important limitation and provides just a 
snapshot of the HIV burden within the Ag85A-specific CD4+ T cell pool and 
warrants further future investigation. However, whilst small effects of MVA85A on 
HIV infection of CD4+ target cells cannot be excluded given the small sample size, 
these data suggest that MVA85A vaccination of healthy HIV-infected individuals 
does not lead to widespread preferential infection and depletion of vaccine-induced 
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CD4+ T cell populations in the periphery. These data are supported by no change in 
surface expression of the HIV co-receptor CCR5 following MVA85A vaccination. In 
addition, the lack of effect of vaccination on chemokine and cytokine levels in 
unstimulated serum supports the interpretation that vaccination with MVA85A did not 
lead to widespread immune activation in this subject group.  
 
We have shown that vaccine-induced immunogenicity, while of moderate magnitude, 
is significantly lower than in healthy HIV-uninfected subjects given the same dose of 
MVA85A. Thus, additional strategies may be required to augment immune responses 
to MVA85A vaccination in the context of HIV infection. Partial reconstitution of the 
immune system with ARVs may improve the response to vaccination. Indeed, this 
study shows that the baseline HIV RNA level is a strong negative predictor of 
summed 85A peptide pool responses at week 24 post-vaccination. In addition, a 
booster vaccination with MVA85A may be required to enhance the vaccine-induced 
immune response. 
 
The functional profile of Ag85A-specific CD4+ T cells observed in this study was 
remarkably comparable to that of healthy HIV-uninfected subjects 19 and M. 
tuberculosis-infected subjects 10, although the response in HIV-infected subjects is 
less durable. IFN-γ and TNF-α are known to be important for protective immunity to 
TB, and these cytokines dominated the MVA85A vaccine-induced CD4+ T cell 
response elicited in the current study cohort. In this study, production of MIP-1β by 
Ag85A-specific CD4+ T cells was not detectable after week 2 post-vaccination. The 
production of multiple cytokines including IL-2 and MIP-1β by HIV-specific CD8+ T 
cells is associated with long-term non-progression, albeit with uncertain causality27.  
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The production of β-chemokines by CD8+ T cells was not assessed here as there were 
no detectable Ag-85A specific CD8+ T cell responses pre- or post-vaccination.  
 
 Vaccine-induced bystander activation of CD4+ T cells in HIV-infected subjects is 
likely to be undesirable because activated CD4+ T cells are at increased risk of HIV 
infection. The overall pattern of cytokine production and the frequency of CMV-
specific CD4+ T cell producing cytokines remained both relatively stable over the 24-
week period following MVA85A vaccination, and comparable to pre-vaccination 
responses (Supplemental Figure 1).  These data suggest that MVA85A vaccination 
does not induce substantial bystander activation of antigen-specific CD4+ T cell 
populations. 
 
Demonstrating the safety and immunogenicity of a new TB vaccine in an important 
target population is a crucial step, but does not mean that the vaccine will be effective. 
However, the data presented here support further safety and immunogenicity studies 
of this candidate vaccine, together with proof-of-concept efficacy trials, in TB and 
HIV endemic areas.  
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TABLE and FIGURE LEGENDS 
 
Table 1 Full inclusion and exclusion criteria. Subjects were required to meet all of the 
inclusion criteria to participate in the study: 
 
Table 2 Subject demographics: Comparison of low and high dose vaccination groups.  
 
Tables 3a and b Local and systemic adverse events: Comparison of low and high 
dose vaccination groups with dose-matched HIV-uninfected subjects from previous 
trials of MVA85A6, 7, 10 (Pathan et al, unpublished data). There were significantly 
fewer systemic AEs per person, (and a lower frequency of systemic AEs overall,) in 
the 10 HIV-infected subjects receiving high dose MVA85A compared with HIV-
uninfected subjects receiving the same dose of vaccine (p=0.026, data not shown and 
Pathan et al, unpublished) 
 
Table 4a Ex-vivo IFN-γ ELISpot statistics (1): Comparison of screening, week 1 and 
week 24 responses within low and high dose groups, for both summed and single 
pooled peptides, using Wilcoxon signed rank test. Median (range), median difference 
(range, of week 1 and week 24 responses compared to screening,) and p-values are 
shown. 
 
Table 4b Ex-vivo IFN-γ ELISpot statistics (2): Comparison of responses between 
HIV-infected and HIV-uninfected subjects, at each time-point and each vaccine dose, 
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using Mann-Whitney U test. Median (range), difference in medians (with 95% 
confidence intervals), and p-values are shown. AUC analysis is also shown. 
 
Figure 1 Flowchart. Follow-up was conducted for 24 weeks post-vaccination in both 
the low dose MVA85A (5x107pfu; left panels) and high dose MVA85A (1x108 pfu; 
right panels) groups. Of the volunteers excluded at screening, 5/15 had CD4 counts 
<350 x 106/L and/or exhibited progressively decreasing CD4 counts, 2/15 had HIV 
RNA loads of >100,000 copies/mL, 2/15 had abnormal chest radiographs, 1/15 had a 
current history of active eczema, and 1/15 had a history of illicit drug usage and 
unstable depression; the remaining 4/15 were eligible but failed to attend for 
vaccination (2 in each dose group).  
 
Figure 2 (a-d) Comparison of pre and post-vaccination CD4 counts: Longitudinal 
CD4 counts of subjects in the low dose (5x107 pfu MVA85A) group pre-vaccination, 
(a); and high dose (1x108 pfu MVA85A) group (c) pre-vaccination. Longitudinal CD4 
counts post-vaccination (up to 24 weeks) in the low dose (b) and high dose (d) 
groups. NB X-axis for the pre-vaccination data is not standardised for time but varies 
from 1-6 years depending on the individual subject.(e-h) Comparison of pre and post-
vaccination HIV RNA loads: Longitudinal HIV RNA loads of subjects in the low dose 
(e) and high dose (g) groups pre-vaccination. Longitudinal HIV RNA loads post-
vaccination (up to 24 weeks) in the low dose (f) and high dose (h) groups. 
Anonymous number codes (001-036) shown in key. NB X-axis for the pre-
vaccination data is not standardised for time but varies from 1-6 years depending on 
the individual subject. 
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Figure 3 (a-d) IFN-γ ELISpot responses in the low dose and high dose groups. 
Longitudinal responses to the single 85A peptide pool are shown for the low dose 
(5x107 pfu MVA85A) group, (a) and high dose (1x108 pfu MVA85A) group (b). 
Longitudinal responses to the summed 85A peptide pools are shown for the low dose 
(c) and high dose (d) groups. Horizontal bars represent the median response.  
Comparison of IFN-γ ELISpot responses in HIV-infected and HIV-uninfected subjects 
(e-g). Responses to summed 85A peptide pools for low dose and high dose vaccine 
regimes at screening (e); week 1 post-vaccination (f) and week 24 post-vaccination 
(g).  Subjects with LTBI are denoted with grey symbols. Statistically significant 
differences in the responses between HIV-infected and HIV-uninfected subjects were 
assessed using the Mann-Whitney U test. *p<0.05; **p<0.01; ***p<0.001. Horizontal 
bars represent the median response6, 7, 10 (Pathan et al, unpublished data).  
 
Figure 4 MVA85A induces polyfunctional Ag85A-specific CD4+ T cells in HIV-
infected individuals. MVA85A vaccination-induced production of IFN-γ, IL-2, MIP-
1β and TNF-α by antigen-specific CD4+ T cells was assessed following Ag85A 
peptide stimulation of cryopreserved PBMC using polychromatic flow cytometry. (a) 
Individual data points are shown with median line, interquartile range (open bars) and 
range (whiskers) at baseline and at each time-point post-vaccination for every 
possible combination of cytokine/chemokine production. High dose and low dose 
groups were analyzed together (n=17). (b) The functional profile of the Ag85A-
specific CD4+ T cell response is summarized in the pie charts (n=17). CD4+ T cells 
producing a given number of cytokines/chemokines are grouped and colour-coded 
together. Pie charts are shown for the high dose HIV-infected group (n=9), the low 
dose HIV-infected group (n=8) and low dose healthy controls (n=6). (c) Absolute 
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percentages of the highest frequencyCD4+ T cell subsets producing specific 
combinations of chemokine/cytokines at week 1 post-vaccination across the different 
groups; * p<0.05, ** p<0.01. 
 
Figure 5 Cytokine/chemokine production and receptor expression 
(a) Absolute percent of Ag85A-specific CD4+ T cells producing IL-2 or MIP-1β at 
week 1 post-MVA85A vaccination in HIV-infected subjects (low dose and high dose, 
n=17) versus healthy controls (n=6). Representative histogram (b) and scatter plot (c) 
showing CCR5 median fluorescence intensity (MFI) in naïve CD4+ T cells, memory 
CD4+ T cells and activated Ag85A-specific CD4+ T cells at  week 1 post- 
vaccination (n=16 in all groups). (d) Scatter plot showing CCR5 integrated MFI 
(iMFI) for naïve, memory and Ag85A-specific CD4+ T cells (n=16). Line charts 
showing CCR5 MFI in memory CD4+ T cells (e) and the total CD4+ T cell 
population (f) across the MVA85A vaccination time-course (n=16). * p<0.05, ** 
p<0.01. 
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Table 1 Full inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Healthy adults aged 18 to 55 years 
• Willingness to allow the investigators 
to discuss the volunteer’s medical 
history with the volunteer’s HIV lead 
physician (and GP, if appropriate) 
• HIV antibody positive; diagnosed at 
least 6 months previously 
• CD4 count >350; nadir CD4 not < 
300 
• HIV viral load not > 100,000 copies 
per millilitre 
• Written informed consent 
 
• Any clinically significant abnormal 
finding on screening biochemistry or 
haematology blood tests or on 
urinalysis 
• Any ARV therapy within the past 6 
months 
• Any AIDS defining illness 
• CXR showing TB or evidence of 
other active infection  
• Prior receipt of a recombinant MVA 
or Fowlpox vaccine 
• Use of any investigational or non-
registered drug, live vaccine or 
medical device other than the study 
vaccine within 30 days preceding 
dosing of study vaccine, or planned 
use during the study period 
• Administration of chronic (defined 
as more than 14 days) 
immunosuppressive drugs or other 
immune modifying drugs within six 
months of vaccination. (For 
corticosteroids, this will mean 
prednisolone, or equivalent, ≥ 0.5 
mg/kg/day. Inhaled and topical 
steroids are allowed.) 
• History of allergic disease or reactions 
likely to be exacerbated by any 
component of the vaccine, e.g. egg 
products 
• Presence of any underlying disease 
that compromises the diagnosis and 
evaluation of response to the vaccine 
(including evidence of cardiovascular 
disease, history of cancer (except basal 
cell carcinoma of the skin and cervical 
carcinoma in situ), history of insulin 
requiring diabetes mellitus, any 
ongoing chronic illness requiring 
ongoing specialist supervision (e.g., 
gastrointestinal), and chronic or active 
neurological disease) 
• History of > 2 hospitalisations for 
invasive bacterial infections 
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(pneumonia, meningitis) 
• Suspected or known current drug 
and/or alcohol abuse (as defined by 
an alcohol intake of >42 units a 
week) 
• Seropositive for hepatitis B surface 
antigen (HBsAg) and/or hepatitis C 
(HCV antibodies) 
• Evidence of serious psychiatric 
condition 
• Any other on-going chronic illness 
requiring hospital specialist 
supervision 
• Administration of  immunoglobulins 
and/or any blood products within 
the three months preceding the 
planned administration of the vaccine 
candidate 
• Pregnant/lactating female and any 
female who is willing or intends to 
become pregnant during the study 
• Any history of anaphylaxis in reaction 
to vaccination 
• PI assessment of lack of willingness 
to participate and comply with all 
requirements of the protocol, or 
identification of any factor felt to 
significantly increase the 
participant’s risk of suffering an 
adverse outcome 
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TABLE 2 
Demographics and screening results Low dose 
5x10
7
pfu 
High dose 
1x10
8
pfu 
Sex Male 
Female 
9 (90%) 
1 (10%) 
8 (80%) 
2 (20%) 
Median age (range) 35.8 (21-52) 35.1 (27-46) 
Continent of Birth Africa 
Asia 
Europe 
North America 
South America 
 
4 (40%) 
0 
4 (40%) 
1 (10%) 
1 (10%) 
 
4 (40%) 
1 (10%) 
5(40%) 
0 
0 
 
BCG Definite 
Uncertain 
7 (70%) 
3 (30%) 
10 (100%) 
0 (0%) 
Latent infection (ESAT-6/CFP-10 +) 2 (20%) 3 (30%) 
Median CD4 count (range) 570  
(430-1200) 
625  
(410-840) 
   
   
Median HIV RNA load (range) 6069 (39-
41890) 
14805 (49-
71090) 
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TABLE 3 
(a) 
Local Adverse Events 
  
HIV-infected 
 
HIV-negative 
Dose 
Number of subjects 
5x10
7
pfu 
n=10 
1x10
8
pfu 
n=10 
5x10
7
pfu 
n=43 
1x10
8pfu 
n=12 
Redness 10 (100%) 10 (100%) 42 (98%) 12 (100%) 
Pruritis 10 (100%) 9 (90%) 22 (51%) 8 (67%) 
Pain 8 (80%) 7 (70%) 36 (84%) 12 (100%) 
Induration 10 (100%) 10 (100%) 42 (98%) 12 (100%) 
 
(b) 
Systemic Adverse Events 
  
HIV-infected 
 
HIV-negative 
Dose 
Number of subjects 
5x10
7
pfu 
n=10 
1x10
8
pfu 
n=10 
5x10
7
pfu 
n=43 
1x10
8
pfu 
n=12 
Measured fever 1 (10%) 0 (0%) 3 (7%) 5 (42%) 
Subjective fever 3 (30%) 2 (20%) 17 (40%) 9 (75%) 
Arthralgia 2 (20%) 3 (30%) 6 (14%) 7 (58%) 
Headache 6 (60%) 4 (40%) 21 (49%) 10 (83%) 
Myalgia 1 (10%) 2 (20%) 18 (42%) 9 (75%) 
Nausea 1 (10%) 0 (0%) 4 (9%) 4 (33%) 
Vasovagal syncope 0 (0%) 1 (10%) 0 (0%) 0 (0%) 
Axillary lymphadenopathy 1 (10%) 0 (0%) 2 (5%) 2 (17%) 
Change in 
haematology/biochemistry 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
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 33 
TABLE 4 
 
(a)  
Summed pooled peptides – within dose changes from screening to peak and plateau 
 
Dose  Screening 
(n=10) 
Week 1 
(n=10) 
Week 24 
(n=10) 
Median (range) 10 (3, 20) 738 (109, 4398) 20 (0, 237) n=9 
Median difference (range) (compared to screening)  730 (109, 4383) 
 
17 (-8, 218) 
n=9 
Low 
p-value*  0.007 0.17 
Median (range) 3 (0, 14) 1730 (758, 2138) 42 (33, 256) 
Median difference (range) (compared to screening)  1721 (743, 2135) 42 (27, 247) 
High 
p-value*  0.005 0.007 
*Wilcoxon signed rank test 
 
Single pooled peptides – within dose changes from screening to peak and plateau 
 
Dose  Screening 
(n=10) 
Week 1 
(n=10) 
Week 24 
(n=10) 
Median (range) 0 (0, 8) n=9 393 (67, 1275) n=9 13 (2, 103) n=9 
Median difference (range) (compared to screening)  393 (60, 1272) 
n=9 
13 (2, 97) 
n=9 
Low 
p-value*  0.009 0.032 
Median (range) 0 (0, 8) 502 (312, 677) 14 (0, 68) 
Median difference (range) (compared to screening)  502 (294, 677) 14 (0, 66) 
High 
p-value*  0.005 0.048 
*Wilcoxon signed rank test 
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(b) 
 
HIV-infected vs. HIV-negative group 
 Summed Pooled peptides Median (range) HIV+ 
 
Median (range) HIV- 
 
Difference in medians 
(95% confidence interval) 
p-value* 
Low dose 738 
(109, 4398) 
n=10 
2147 
(1173, 5085) 
n=21 
1101 
(-393, 2873) 
0.12 Week 1 
High dose 1730 
(758, 2138) 
n=10 
6493 
(4854, 7312) 
n=12 
4557 
(3038, 5904) 
0.0001 
Low dose 20 
(0, 237) 
n=9 
385 
(228, 1010) 
n=20 
339 
(161, 534) 
0.004 Week 24 
High dose 42 
(33, 256) 
n=10 
970 
(655, 1199) 
n=12 
820 
(569, 1050) 
0.0001 
Low dose 2162 
(519, 23348) 
n=9 
16317 
(9129, 36418) 
n=20 
11884 
(3191, 17387) 
0.02 Area under the curve 
High dose 5929 
(3167, 11607) 
n=10 
41575 
(26919, 53807) 
n=12 
31384 
(20778, 45504) 
0.0001 
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